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Adverse Drug Reactions (ADRs) are a global health problem and a leading cause of death, 
illness and injury in economically developed countries. Therapeutic response, as well the 
occurrence of undesired effects, can differ significantly between children and adults and 
many drugs have not been sufficiently studied in the paediatric population. Existing studies 
on ADRs in children differ widely in study design and outcome reporting, and many are 
methodically problematic. 
The incidence and characteristics of ADRs in hospitalised children and factors associated 
with an increased risk of experiencing and ADR, were assessed in a large, prospective, 
observational study. 17.7% of all children experienced at least one ADR. Opiate analgesia 
and drugs used in general anaesthesia (GA) accounted for more than 50% of all drugs 
implicated in ADRs. Less than 1% of ADRs caused permanent harm or required admission to 
a higher level of care. Children post GA were more than six times more likely to experience 
an ADR than children who had not received a GA (HR 6.38; 95%CI 5.3-7.7). Other risk factors 
identified were increasing age (HR 1.05 for each year; 95%CI 1.04-1.07), increasing number 
of medicines (HR 1.25 for each additional medicine; 95%CI 1.22-1.28) and being an oncology 
patient (HR 1.89; 95%CI 1.36-2.63). The proportion of ADRs caused by GA agents and opiate 
analgesia has previously been underestimated. 
The cost of excess bed days due to ADRs, has been estimated to be £2 Million per year for a 
400-bed adult hospital. The cost of excess bed days in our study was only £35,000 per year 
for a 300-bed hospital. Other parameters and methods might need to be considered when 
assessing the financial impact of ADRs in children. 
Cisplatin is used in cancer treatment and causes irreversible hearing loss in 42-88% of 
children. Cathechol-O-Methyltransferase (COMT) and Thiopurine-S-Methyltransferase 
(TPMT) genetic variants have been associated with hearing loss in paediatric patients, but 
findings from subsequent studies are contradictory. The occurrence of COMT and TPMT 
genetic variants in a UK population was examined in a retrospective, multicentre cohort 
study. Known risk factors for ototoxicity were confirmed; increasing cumulative dose of 
cisplatin younger age (p< 0.01), cranial radiotherapy (p <0.028) and exposure to vincristine 
p< 0.091). The association with COMT and TPMT genetic polymorphisms could not be 
replicated. 
ADRs in children are common and improving medicines safety in children remains a vital 
aspect of clinical care. New assessment tools are aiming to address some of the challenges 
faced by clinicians and researchers. Our knowledge of pharmacokinetics and 
pharmacodynamics in children is still limited, but advances in the field of paediatric 
pharmacogenomics are beginning to translate into improved medicines safety and efficacy 
for children. Further work about non-Oncology ADRs would benefit from a focus on high 
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Adverse drug reactions (ADRs) are an important cause of iatrogenic morbidity and mortality 
in patients of all ages.  
In the in the United Kingdom (UK), ADRs account for 6.5% (95% confidence interval (CI), 6.2-
6.9%) of acute hospital admissions in adults (Pirmohamed et al. 2004) and 2.9% (95% CI, 2.5- 
3.3%) in children (Gallagher et al. 2012). In comparison, coronary heart disease accounted 
for 4.9% of emergency admissions in England in 2001 (The British Thoracic Society 2006) and 
asthma for 3.8% of emergency admissions in children in Scotland in 2005/06 (Information 
Services Division (ISD) Scotland 2009).  
A large, prospective, in-patient study in adults in the United Kingdom (UK) found that in 1 of 
7 hospital episodes at least one ADR occurred (incidence 14.7%; 95% CI, 13.6-15.9%) (Davies 
et al. 2009) and that ADRs contributed to 14 of 184 deaths (0.4% of patients admitted). Based 
on an average cost of bed days, the financial impact of ADRs per (adult) hospital per bed per 
year has been estimated to be £5000 in the UK, € 5580 in France and $8000 in the US  (Bates 
et al. 1997; Davies et al. 2009; Moore et al. 1998).  
There are no comparable paediatric in-patient data. As part of the ADRIC programme, Smyth 
et al. conducted a systematic review of ADR studies in children (Smyth et al. 2014; Smyth et 
al. 2012) which is summarised below (1.5). Firstly, however, it would seem important to 
understand how ADRs and some aspects of drug safety are different in children compared 
to adults. Secondly, comparing data from different studies (in children as well as adults) can 
be problematic due to different study designs. Therefore, key aspects of ADR assessment 
and definitions of drug safety will also be discussed. 
The evidence presented and discussed in this chapter will focus on the literature available at 
the time the author of this thesis commenced her studies. An exception are citations from 
webpages and results of studies that were part of the ADRIC programme as these were 
available to the author of this thesis prior to their publication. 
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1.1 ADRs in children  
ADRs in children can differ from those in adults due to age dependent physiological 
characteristics which affect pharmacokinetics (PK) and pharmacodynamics (PD) of 
medication. There are numerous examples to illustrate this. Tetracyclines for example are 
contraindicated in young children and pregnant women as they cause staining of teeth in 
the newborn or growing child (Demers et al. 1968). Chloramphenicol caused ‘grey baby-
syndrome’ (Sutherland 1959) due to impaired metabolism in neonates. Dystonia and 
dyskinesia due to metoclopramide is significantly more common in young adults (Bateman, 
Rawlins & Simpson 1985). In an analysis of 42 cases of sodium valproate induced fatal 
hepatitis, 69% of patients were 10 years old or less at presentation (Powell-Jackson, Tredger 
& Williams 1984). More recently, the death of three infants aged ≤ 6 months has been 
associated with pseudoephedrine in cough and cold medications (Srinivasan et al. 2007). 
The importance of developmental pharmacology has been recognised for more than a 
century (Kearns et al. 2003), but only recent changes in legislation have provided and 
incentive to collect specific data in the paediatric population (Hawcutt & Smyth 2008). A 
hallmark in European legislation was the regulation on medicinal productions for paediatric 
use in 2007 (Union 2006). A paediatric investigation plan (PIP) is now mandatory for all 
medicines under development in Europe. Waivers are granted for medicines unlikely to 
benefit children such as medication used in the treatment of Alzheimer’s disease. In 
addition, the new legislation also offers incentives for the development of off-patent 
medicines. However, such changes in legislation are likely to take some time to show an 
effect as the majority of medications, currently prescribed for children, predate this 
legislation.  
1.2 Drug safety  
To improve the safety of medicines in adults as well as children, post marketing evaluation 
is as important as well conducted clinical trials prior to marketing. To identify ADRs that 
occur at a rate of 1/3,000-6,000, statisticians estimate that 10,000-20,000 patients would 
need to be monitored (Severino & Del Zompo 2004), therefore the full ADR profile of new 
medicine can often only be known after many years and it is generally accepted that at least 
2-3 years of post-marketing surveillance are required (Lasser et al. 2002). Many countries 
have therefore established spontaneous post-marketing reporting systems, such as the 
MHRA’s yellow card scheme in the UK, but underreporting remains common (Hazell & Shakir 
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2006). Although international collaborations such as the World Health Organisation’s (WHO) 
Uppsala Monitoring Centre (UMC) are addressing this issue, systematic studies into the 
incidence and character of ADRs occurring in the population are of particular importance, 
not least to highlight areas where further research is required.  
The branch of pharmacological science concerned with all aspects of drug safety is 
Pharmacovigilance, ‘the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem’ (World 
Health Organisation 2004). 
1.3 Definitions  
One of the earliest aims within the field of pharmacovigilance has been to agree on 
definitions of the terms ‘adverse event’, ‘adverse drug reaction’ and ‘adverse drug event’, to 
improve communication in clinical trials, research and in the clinical context. Although 
worldwide accepted definitions now exist, they still do not necessarily reflect their 
application in clinical practice (Smyth et al. 2014). It is important to take this into account 
when conducting clinical research (outside clinical trials) or translating research into clinical 
practice. 
1.3.1 Adverse event (AE) 
The following definition has been agreed by the International Council on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) with input 
from the WHO: ‘Any untoward medical occurrence in a patient […] administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship 
with this treatment.’ (ICH 1995). The relationship between medicinal product and event is 
therefore temporal and may or may not be causative.  
1.3.2 Adverse drug reaction (ADR) 
A widely accepted definition of ADR is WHO’s definition from 1972: ‘A response to a drug 
which is noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological 
function.’ (World Health Organisation 1972)  
Edwards and Aaronson developed this definition further by defining the word ‘noxious’ more 
clearly and including excipients or contaminants as potential causes of reactions rather than 
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the drug alone by replacing the word ‘drug’ with the ‘medicinal product’. In their definition, 
which is also widely used, an ADR is  ‘an appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the 
dose regimen, or withdrawal of the product’ (Edwards & Aronson 2000). Both definitions of 
ADR imply causality between medicinal product and reaction and exclude reactions due to 
medication error, prescribing error or overdose. 
In clinical practice, the terms ‘side-effect’ and ‘ADR’ are often used interchangeably. 
However, ‘side-effect’ may refer to desirable as well as undesirable effects. It may also result 
in prescribers and patients considering it unavoidable, that a harmful, unintended reaction 
occurs in addition to the intended, therapeutic effect. Although it would perhaps be 
desirable to avoid the term ‘side-effect’ altogether, it remains the most commonly used term 
for ADRs in clinical practice. This is reflected in the its use in WHO fact sheets on vaccinations 
and medicines (World Health Organisation 2016), and in the explanation given on the MHRA 
website: ‘Suspected side effect, also known as adverse drug reaction. These are unwanted 
effects that you consider are linked to taking a medicine. Side effects also include any effects 
from: misuse, abuse, an error in the way the medicine has been given or overdose’(MHRA 
2016).  
1.3.3 Adverse drug event (ADE) 
The generally accepted definition of ADE is ‘an injury due to medication’ or in the original 
wording of Bates et al. (Bates et al. 1995) ‘injury resulting from medical intervention related 
to a drug’ . It implies a causal relationship between drug and event. Harm may occur due to 
medication use as well as due to dose reduction or discontinuation. Furthermore, 
prescribing and administration errors, as well as accidental or deliberate overdoses, are 
included in this definition. Therefore, all ADRs are ADEs but the reverse is not true.  
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1.4 Evaluation of ADRs 
When investigating reactions suspected to be ADRs, there are three important concepts:  
1. Establishing a causal probability (causality) between the suspected medicinal 
product(s) and the reaction.  
2. Assessment and classification of the seriousness and severity of the ADR.  
3. Assessing the preventability (or avoidability) of the ADR. 
Reaching agreement on these aspects remains a challenge of pharmacoepidemiologic 
research. Significant disagreement can be observed whenever judgement is made without 
referring to agreed definitions and/or the structure of validated assessment tools or 
classifications (Arimone et al. 2005; Aronson & Ferner 2005; Ferner & Aronson 2010).  
1.4.1 Causality of ADRs 
Numerous methods to assess the causal probability between a drug and a suspected ADR 
have been published, none of which has been universally accepted (Agbabiaka, Savović & 
Ernst 2008). The approaches used can be divided into three categories: Expert judgement, 
algorithms and probabilistic approaches.  
1.4.1.1 Expert judgement 
Traditionally, most studies have used expert judgement to determine ADR causality often 
involving only a single assessor. This method is dependent on knowledge and experience 
and renders poor reproducibility and reliability (Arimone et al. 2005). Structured 
communication approaches, such as the Delphi technique, employing a panel of experts and 
using a systematic procedure order to reach consensus, are more reliable (Arimone et al. 
2005) However, this is time consuming and therefore not feasible as first line assessment in 
larger studies or in post-marketing surveillance operations. Furthermore, a panel of experts 
may reach consensus but the judgement may still be wrong.    
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1.4.1.2 Algorithms 
In a landmark address to the ‘newly-founded Section of Occupational Medicine’, Sir Austin 
Bradford Hill discussed nine concepts of association between environmental factors and 
disease that should be examined when making a judgement on causation (Hill 1965). He 
considered them viewpoints rather than necessary conditions that could bring ‘indisputable 
evidence for or against the cause and effect hypothesis’(Hill 1965). These viewpoints are 
now generally referred to as (Bradford) Hill criteria:  
1. Strength of association 
2. Consistency of the observed association  
3. Specificity 
4. Temporality 
5. Biological gradient (dose-response curve) 
6. Plausibility 
7. Coherence (data should not conflict with the natural history of the disease),  
8. Experiment (experimental evidence)  
9. Analogy (ready to accept slighter but similar evidence with another disease or 
drug)  
Algorithms, often depicted as flow-charts, are based on a set of steps that need to be 
followed in order to arrive at a conclusion or solution of a problem, building on several, but 
rarely all, of the above criteria. However, In their systematic review of methods of causality 
assessments, Agbabiaka et al. (Agbabiaka, Savović & Ernst 2008) examined 26 algorithms 
and found that the majority of authors included questions about the temporal sequence 
(17/26), re-challenge  (17/26) and the response pattern (17/26). About 50% also included 
questions about drug levels (14/26) and de-challenge (12/26) and at least one third 
incorporated previous exposure (11/26) and confirmation by laboratory evidence (10/26) as 
part of their algorithms. Algorithms are reproducible, relatively easy to use and have 
demonstrated higher rates of inter-rater agreement (Hutchinson et al. 1983) However there 
is no way to include additional information and a degree of clinical judgement is usually still 
required for some questions e.g. when considering alternative causes. In addition, specific 
problems have been identified in individual algorithms, for example: 
• Naranjo (Naranjo, Busto & Sellers 1981): Weighting of questions without providing a 
rationale and inclusion of questions that are no longer relevant (Gallagher et al. 2011) 
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• Karch and Lasagna (Karch & Lasagna 1977): Inability to identify new ADRs (Agbabiaka, 
Savović & Ernst 2008) 
• Kramer (Kramer et al. 1979): Level of expertise and experience required (Agbabiaka, 
Savović & Ernst 2008; Leventhal et al. 1979)   
In an attempt to overcome some of these issues and as part of the ADRIC programme, 
Gallagher et al. developed a new causality assessment tool (Liverpool CAT or LCAT), that is 
easy to use and has shown good inter-rater reliability (Gallagher et al. 2011).  
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1.4.1.3 Probabilistic approaches 
Probabilistic approaches are mostly based on Bayes’ theorem, which means that the 
probability of an ADR having occurred is calculated by firstly considering the probability of 
the reaction (occurring with and without exposure to the drug) and by secondly considering 
the available evidence given for each case. Likelihood ratios are calculated for each factor; a 
final estimate of the reaction having occurred as a results of the exposure to the drug is then 
calculated (Arimone et al. 2005). Although these approaches are reliable and highly 
reproducible, probabilistic  methods are time consuming,  complex and resource intense 
(Agbabiaka, Savović & Ernst 2008) which limits their use as general ADR assessment tool .  
In the absence of a single, universally accepted causality assessment, combining methods is 
perhaps the best possible approach to yield the most reliable results. It would for example 
be feasible to employ a suitable algorithm in the first instance and use the Delphi technique 
or a probabilistic approach for cases of particular interest.  
1.4.2 Seriousness and Severity of ADRs 
Classifying the seriousness of an ADR is important as it is a measure of describing the harm 
an ADR has caused or has the potential to cause. According to ICH guidelines, a serious ADR 
is ‘any reaction that results in death, is life-threatening (i.e. the subject was at risk of death 
at time of the event), requires hospitalisation or prolongation of existing hospitalisation, 
results in persistent or significant disability or incapacity, is a congenital anomaly or birth 
defect or is medically significant’ (ICH 1995). These outcome categories for seriousness are 
used in clinical trials (NETSCC 2016) as well as post-marketing reports of ADRs (MHRA 2016). 
Severity or intensity of an ADR assesses the extent of the reaction with regards to the 
individual patient. Serious reactions are usually severe, but severe reactions need not be 
serious. The classic example used to illustrate the difference between those terms is 
‘headache’. A headache may be experienced as severe by the patient and therefore rate 
highly on a visual analogue pain scale, but is usually not serious. Severity scales using 
categorise such as ‘trivial’, ‘mild’, ‘moderate’ and ‘severe’ are of little value, as they are 
subjective and no satisfactory definitions exist (Aronson & Ferner 2005). In 1992, Hartwig et 
al. proposed a numbered, 7-level rating scale (Hartwig, Siegel & Schneider 1992) (Table 1.1). 
In levels 1-3 the effect the ADR has on the treatment is considered (no change in treatment, 
change in treatment, change in treatment and antidote/additional treatment), whereas 
levels 4-7 incorporate categories of increasing seriousness (admission or prolonged stay, 
 9 
admission to intensive care, permanent harm, death). One could therefore argue that the 
Hartwig scale is a combined seriousness and severity assessment scale. 
More recently, Ferner and Aaronson proposed a classification that is firstly based on 
alteration of the dosage regimen and secondly on the response to treatment if this was 
required (Aronson & Ferner 2005) (Table 1.2). In contrast to Hartwig’s classification, terms 
referring to the seriousness of the ADR are avoided altogether. Most clinical studies 
investigating ADRs that have made use of severity and/or seriousness assessment tools to 
date are using a modified form of the Hartwig scale.  This is unsurprising, given that the 
Hartwig scale has been established much longer. From a clinical and pharmacovigilance 
point of view, it is also perhaps more important to describe the seriousness of an ADR than 
purely assessing its severity. 
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Table 1.1 ADR Severity Assessment Scale (Hartwig, Siegel & Schneider 1992) 
Level Description  
1 
An ADR occurred but required no change in treatment with the suspected 
drug. 
2 
The ADR required that treatment with the suspected drug be held, 
discontinued, or otherwise changed. No antidote or other treatment 
required, no increase in length of stay (LOS). 
3 
ADR required that treatment with suspected drug be held, discontinued, or 
otherwise changed AND/OR an antidote or other treatment was required. 
No increase in LOS. 
4 
(A) Any level 3 ADR which increases LOS by at least 1 day.  
OR:  
(B) The ADR was the reason for admission. 
5 Any level 4 ADR which requires intensive medical care. 
6 The adverse reaction caused permanent harm to the patient. 
7 
The adverse reaction either directly or indirectly led to the death of the 
patient. 
 
Table 1.2  ADR Severity (Intensity) Classification (Aronson & Ferner 2005) 
Grade Change in dosage regimen of the 
offending drug  
Treatability of the reaction 
1 No change in dosage regimen required A. No treatment required  
  B. Relieved or partly relieved by 
treatment 
  C. Not relieved by treatment 
2 Altered dosage regimen required or 
desirable 
A. No treatment required  
  B. Relieved or partly relieved by 
treatment 
  C. Not relieved by treatment 
3 Withdrawal required or desirable A. No treatment required  
  B. Relieved or partly relieved by 
treatment 
  C. Not relieved by treatment 
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1.4.3 Avoidability of ADRs 
Several approaches to determine the preventability of ADRs exist. The most commonly used 
definitions are those described by Schumock & Thornton (Schumock & Thornton 1992) and 
Hallas (Hallas et al. 1990) (Table 1.3 and Table 1.4). They are both based on appropriateness 
of prescribing and both include medication errors (questions 2-4 and 6 in Table 1.3 and 
definition of ‘definitely avoidable’ in Table 1.4). Although harm arising from, for example, 
prescription or administration error is preventable and hence constitutes a crucial aspect of 
drug safety, as per definitions discussed above (1.3) this concern ADEs but not ADRs. 
Assessing the appropriateness of the prescription is not necessarily straightforward, in 
particular in the context of paediatric prescribing. From the outset, it is not clear whether 
the appropriateness of prescribing should be considered prospectively or retrospectively. 
For example, a febrile infant, with a later confirmed viral infection, may well have been 
prescribed an antibiotic, on admission, to which the child developed a reaction. The reaction 
may therefore either be considered avoidable, as antibiotic treatment was not indicated or 
unavoidable, if prescribing an antibiotic was considered appropriate in view of the clinical 
presentation. Furthermore, if one concludes that the prescription was not indicated in the 
first place this could then be considered an error and hence a preventable ADE.  
Schumock also includes assessment of the appropriateness of dose, route or frequency 
(question 2 in Table 1.3) which represents a further challenge in the paediatric context, 
where off-label and unlicensed prescribing is very common and hence might be impossible 
to answer this question. Hallas’ criteria require further explanation as terms like ‘reasonable 




Table 1.3 Criteria to determine the preventability of ADRs (Schumock & Thornton 1992) 
An answer of ‘yes’ to one or more of the following questions indicates that the ADR may 
indeed have been preventable.  
1. Was the drug involved in the adverse drug reaction not considered appropriate for the 
patient’s clinical condition?  
2. Was the dose, route, and frequency of administration not appropriate for the patient’s 
age, weight and disease state? 
3. Was required therapeutic drug monitoring or other necessary laboratory testing not 
performed?  
4. Was there a history of allergy or previous reactions to the drug?  
5. Was a drug interaction involved in the reaction?  
6. Was a toxic serum drug level documented?  
7. Was poor compliance involved in the reaction? 
 
Table 1.4 Criteria for avoidability (Hallas et al. 1990) 
Definitely 
avoidable 
The event was due to a drug treatment procedure inconsistent with 
present-day knowledge of good medical practice or was clearly 
unrealistic, taking the known circumstances into account 
Possibly 
avoidable 
The prescription was not erroneous, but the event could have been 
avoided by an effort exceeding the obligatory demands 
Not avoidable 
The event could not have been avoided by any reasonable means, or 
was an unpredictable event in the course of a treatment fully in 
accordance with good medical practice 
Unevaluable 





Ferner and Aronson recently conducted a systematic review of preventability of ADRs and 
concluded that ‘there is no simple method’ to characterise preventability of ADRs (Aronson 
& Ferner 2010). In addition, reliability for any of the currently existing criteria is not ideal 
and none of the current criteria can be applied universally (Ferner & Aronson 2010). 
Consequently they proposed a new and different approach, taking into account four key 
aspects (Aronson & Ferner 2010): 
• Preventability according to mechanism 
• Preventability according to individual susceptibility 
• Preventability according to time-course 
• Preventability according to dose-response pattern 
Their approach can be applied retrospectively, e.g. on ADR case reports, as well as 
prospectively. Although a new approach to define avoidability is clearly needed, Ferner and 
Aronson’s approach is complex and requires knowledge which might not be readily available 
for paediatric patients, such as (age dependent) PK and PD data. In addition, the amount of 
in depth knowledge required overall to assess a reaction, will make it unlikely that this tool 
can be easily used in large scale ADR studies involving many different medications and 
patients.  Furthermore, clinicians without a background in pharmacology or pharmacy are 
unlikely to be able to use this approach independently.   
There remains an urgent need for a novel assessment approach for avoidability of ADRs, 
ideally taking into account the unique conditions of paediatric prescribing. 
1.5 Studies investigating ADRs in children 
Taking the above into account it is unsurprising that after analysing 101 paediatric studies 
investigating ADRs, Smyth et al. concluded, that although a large number of studies exists, 
they differ widely, a high proportion has major shortcomings in design and/or reporting and 
hence only limited and cautious conclusions and recommendations can be made. (Smyth et 
al. 2014; Smyth et al. 2012). The review confirmed, that ADRs are a significant problem in 
children. 
Smyth et al. analysed the studies according to 1) study design, methods and setting 2) 
definition, incidence and evaluation of ADRs and 3) clinical presentation, drug classifications 
and risk factors. The observed study periods ranged from 1 day to 11 years. 84 studies were 
carried out prospectively, 14 retrospectively, two used both approaches and for one study 
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this information was not obtainable. Studies investigated ADRs in community settings 
(n=35), in patients admitted to hospital (n=53) or as cause of admission to hospital (n=42), 
with several studies using combined settings. 62 studies used a clinician, i.e. a medical 
doctor, nurse or pharmacist, to identify ADRs and 30 studies included children and/or 
carer(s) in the identification process. Methods for detection of ADRs varied considerably. 58 
studies used a combination of different sources such as parental/patient/clinician 
interviews, case note reviews, computerised reporting systems or attendance ward round. 
41 used only a single source and for one study there was no information given.  
Overall, a large proportion of the studies examined by Smyth et al. did not report data on 
seriousness, causality and avoidability of ADRs in a paediatric population: 71 studies 
commented on causality assessments but only 36 studies reported complete causality data. 
34 studies reported a severity assessment, however, 14 of these did not provide details of 
the classification system used. Severity of ADRs was assessed in 34 studies, with 0-67% of 
ADRs reported as severe. Usually ADRs considered serious under ICH criteria (1.4.2)  were 
reported as severe. Only 14 of 101 studies provided avoidability data and this might well 
reflect the lack of suitable preventability assessment tools. The proportion of ADRs classified 
as possible or definitely avoidable ranged widely from 7% to 98%.  
36 of 51 studies investigating ADRs in hospitalised children provided incidence rates, ranging 
from 0.6% to 16.8% of patients as shown in Figure 1.1. 
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Figure 1.1  ADR incidence in hospitalised paediatric patients taken from Smyth et al. 2014 
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1.6 Pharmacogenomics of ADRs 
Regardless of definitions, study design and reporting practices, it is obvious that only a 
proportion of all patients receiving medication experience ADRs. By identifying the 
influencing factors for this person-to-person variability, it may be possible to ameliorate or 
even avoid ADRs all together. Contributing factors are non-genetic, such as environmental 
factors, age, gender, co-morbidities, drug-drug interactions and other clinical factors or 
genetic. The ‘study of variability in drug response due to heredity’ was first called 
pharmacogenetics (Nebert 1999). Later, the broader term pharmacogenomics was 
introduced, with both terms often being used interchangeably in the literature (Pirmohamed 
2001). Pharmacogenomics can be defined as ‘the study of the variability of the expression of 
individual genes relevant to the disease susceptibility as well as drug response at cellular 
individual or population level’(European Medicines Agency 2002).  
Classical examples of the clinical importance of pharmacogenomics are the discovery of 
pseudocholinesterase as cause of prolonged muscle relaxation (Kalow & Gunn 1959) and 
drug-induced haemolytic anaemia in patients with Glucose-6-phosphate-dehydrogenase (G-
6-PD) deficiency (Carson et al. 1956). The identification of these variants started with the 
observation of a distinct ADR, a ‘phenotype’, occurring only in a percentage of patients 
receiving the drug. In the case of G6PD deficiency, it had been noted that haemolysis 
occurred in about 10% of individuals of African origin but only rarely in those of Caucasian 
origin. This lead to the hypothesis of an intrinsic, inherited cause for this ADR and 
subsequently to the discovery of the enzyme, G6PD.  
1.6.1 Genetic variants 
The most common inherited genetic variants are polymorphisms. A polymorphism, that is 
the occurrence of two or more alleles at one locus, originates from a mutation. In its simplest 
and most common form this is a single base mutation, where one nucleotide (A, G, C or T) 
has been exchanged by another. If such a mutation occurs in 1% or more of the population, 
it is then called a ‘single nucleotide polymorphism’ (SNP) (Schork, Fallin & Lanchbury 2000).  
SNPs occur approximately every 300 nucleotides. Considering that there are 3 billion 
nucleotides in the human genome (The International Human Genome Sequencing 
Consortium 2010), there are an estimated 10 million SNPs. It is estimated that less than 1% 
of these are found within exons and hence may or may not affect the amino-acid (AA) 
sequence and the resulting protein (Sachidanandam et al. 2001). However, SNPs do not have 
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to change the AA sequence of a protein to lead to increased susceptibility to a reaction or 
disease (Sparsø et al. 2009; Xiong et al. 2009).   
1.6.2 Candidate gene approach and genome wide studies 
Many pharmacogenomic discoveries have been made by candidate gene approaches. 
Typically, this approach is used for predictable (from known pharmacology) and dose-
dependent ADRs. The DNA of patients who develop a certain ADR (cases) and unaffected 
patients (controls) is tested for genetic variants (mutations or SNPs) in genes known to be 
involved in the pathway of the drug (e.g. receptors, transporters, enzymes, or channel 
proteins). One of the limitations of a candidate gene based approach is, that ADRs which are 
unpredictable and do not exhibit a simple dose-response relationship, also called 
idiosyncratic reactions, can only be tested for genetic variants that are already known (and 
associated with the same type of reaction). To identify new associations, much larger, ideally 
genome-wide approaches need to be employed. This has been facilitated through advances 
in genetic sequencing techniques and the development of genetic microarrays. A well-
characterised phenotype is crucial for genome wide association studies (GWAS), which 
allows more than one million of SNPs to be tested simultaneously for association with the 
observed ADR. The results are then compared to the SNP frequencies in DNA samples of 
unaffected individuals (controls) or against the results of publicly available databases such 
as the HapMap project (The International HapMap Consortium). The GWAS approach is 
bound to generate a multitude of false positive results, therefore associations below a 
certain p-value threshold are generally considered significant and associations above this p-
value of are considered false positives (Becquemont 2009). Currently p-values of  5x 10-8 
are used as significance level for replication (Hoggart et al. 2008) and corrected p-values of 
 1x10-7are generally not considered significant (Becquemont 2009). However, this is based 
on the assumption that the study is sufficiently powered to detect the association between 
SNP and ADR in the first place. Sample size calculations for GWASs are based on assumptions 
regarding the prevalence of the expressed phenotype, the minor allele frequency (MAF), the 
model of inheritance (dominant, recessive, additive etc.), the effect size of the actual genetic 
variant (expressed as relative risk or odds ratio) and error rates (Gail et al. 2008; Pfeiffer & 
Gail 2003; Spencer et al. 2009). Furthermore, linkage disequilibrium (LD) between SNPs has 
to be taken into account (Spencer et al. 2009). Any errors in the study size calculation leading 
to an under-powered study, may lead to true genotype-phenotype associations not being 
detected as they remain ‘hidden’ within a large group of false positive results. GWAS 
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approaches are therefore limited in their power to detect rare genetic variants if the effect 
size is small (Spencer et al. 2009). 
1.6.3 Genotype-phenotype relationship 
Genotype-phenotype relationships are mostly complex. Of several patients carrying the 
same genetic variant, some might develop the ADR and others might not. Conversely, within 
a group of patients without the genetic variant, some might still develop the same ADR. Even 
if an ADR has been shown to be associated with a particular genotype, carrying this genotype 
usually only increases the likelihood of developing the ADR.  
Differences in drug response and/or the occurrence of an ADR, can often be related to 
various pharmacokinetic and/or pharmacodymanic factors and therefore several genetic as 
well as non-genetic factors are influential. Depending on how many other factors influence 
the occurrence of the ADR or drug-response and how much these contribute each, the effect 
size of a given genetic variant may be small or large.  
The example of primaquine-induced acute haemolytic anaemia in individuals with G6PD 
deficiency illustrates some of the aspects that can influence a given genotype-phenotype 
relationship:  
• One phenotype might be associated with several different genotypes. Example: G6PD 
deficiency leads to reduced enzymatic activity of G6PD and may be caused by one of 
many genetic variants (Hoffbrand & Moss 2011)  
• Different genetic variants of the same gene may lead to variation in phenotype. 
Example: The degree of activity reduction in G6PD can vary depending on the genotype 
with some forms causing milder forms of haemolysis  
• Ethnicity may account for or at least contribute to observed differences in drug 
response.  Example: the prevalence of G6PD deficiency is much higher in individuals of 
South-East Asian, African, and Middle-Eastern origin (Hoffbrand & Moss 2011) 
• The reaction (phenotype) may be dose-dependent phenotype. Example: The degree of 
haemolysis can vary depending on the drug dose given.  
• The same drug given to the same patient might not produce the same reaction every 
time (variable phenotype): Example: G6PD activity decreases with time, even in ‘normal’ 
patients (red cell aging). A large proportion of young red cells in the peripheral blood 
e.g. once the patient is recovering from an episode of acute haemolysis, can therefore 
give the appearance of falsely high G6PD activity (Hoffbrand & Moss 2011). In addition, 
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if the patient is exposed to the drug again at this stage, haemolysis can be expected to 
be less severe.  
• Other drugs in the same drug class as well as drugs from other drug classes may cause 
the same reaction - Example: chloroquine can also cause haemolyis (Youngster et al. 
2010) as well as sulphonamides or rasburicase (Youngster et al. 2010).  
• Factors other than medication may produce the same phenotype and could potentially 
lead to misclassification. Example:  Acute illnesses often cause haemolysis independent 
of drug exposure (Youngster et al. 2010).  
Given the variety of influencing factors, some of which are listed above, it is unsurprising, 
that is has often proven difficult to replicate findings of both, candidate gene approaches 
and GWAS (Siontis, Patsopoulos & Ioannidis 2010). Defining accurate phenotypes remains 
the most crucial prerequisite of pharmacogenomic studies (Gurwitz & Pirmohamed 2010). 
1.6.4 Pharmacogenomics of ADRs in children 
An added challenge in the paediatric population is ‘ontogeny’, the process of growth and 
development of an individual from embryo to mature adult. As much as children change in 
their appearance from infancy to adulthood, there are age related differences in body 
proportions and composition, functional body system and organ functions as well as 
individual enzymes, transporters and carriers, all of which can affect drug metabolism. 
Although the individual DNA sequence remains fixed, the expression of genes can vary with 
age. A well-known example is the cytochrome P450 (CYP) superfamily of oxidative enzymes. 
In addition to variable inter-individual expression of in CYP enzymes, there is significant age 
dependent differences in expression of some CYP genes. CYP enzymes are predominantly 
found in the liver and total the amount of cytochrome P450 in the fetal liver is about 30-60% 
of that observed in adults (Hines & McCarver 2002). Although fetal liver contains fewer CYP 
forms, some CYP genes are only found in the fetal liver (Hakkola et al. 1994). Some CYP genes 
are expressed at low levels in the fetal liver and expression increases shortly after birth, the 
expression of other CYP genes increase gradually over time and reaches adult levels around 
puberty (Hines & McCarver 2002). CYP1A2 activity , for example, is nearly undetectable in 
fetal liver, increases after the neonatal period and reaches about 50% of adult activity after 
the first year of live (Dorne, Walton & Renwick 2001). Caffeine and Theophylline metabolism 
for example is predominantly driven by hepatic CYP1A2. Therefore, neonates, are at much 
higher risk of caffeine toxicity (Dorne, Walton & Renwick 2001).    
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There numerous additional examples to illustrated that PK data for children cannot simply 
be extrapolated from adult data and that the lack of available data is likely to put children at 
higher risk of toxicity as well as treatment failure.  In addition, some diseases e.g. Kawasaki’s 
disease, and some forms of cancer e.g. neuroblastoma, occur predominantly in children 
whereas other disease are exclusively found in adults such as Alzheimer’s disease or 
Parkinson’s disease.  
Paediatric specific pharmacogenomic studies are therefore required to improve overall drug 
safety and efficacy in children. 
1.6.5 Pharmacogenomics and paediatric oncology  
One area of paediatric medicine with particularly high rates of serious ADRs is paediatric 
oncology medicine. Cytotoxic drugs account for over 40% of ADRs causing hospital admission 
(Gallagher et al. 2012) and 40% of cancer survivors have experienced a life-threating ADR or 
sustained permanent harm from an ADR (Geenen et al. 2007). Numbers are on the rise as 
survival rates of childhood cancer have improved significantly over the last few decades. The 
overall 5 year survival rates for children between 1 and 14 years increased from around 60 
% in 1975 - 1978 to over 80% in 1999-2002 (Smith et al. 2010) . In 2005 24% of all survivors 
of childhood cancer had survived more than 30 years (Mariotto et al. 2009) and ADRs are 
contributing significantly to long term morbidity and reduced life expectancy (Geenen et al. 
2007) in this patients. Drug specific examples for serious cytotoxic ADRs in paediatric cancer 
patients are anthracycline induced cardiotoxicity (Kremer et al. 2002) which may require 
heart-transplantation; cisplatin induced irreversible ototoxicity (Skinner et al. 1990),  which 
may lead to significant lifelong disability (Berg, Spitzer & Garvin Jr 1999);  and  vincristine 
induced peripheral neuropathy , which may even be fatal (Tarlaci 2008).  
On the other hand, paediatric oncology is an area of paediatric medicine in which 
pharmacogenomic research has successfully been translated into clinical practice: 6-
Mercaptopurine (6-MP), used in the treatment of all children with acute lymphoblastic 
leukaemia (ALL), is metabolised by TPMT. Approximately 0.3% of the population is TPMT 
deficient (Weinshilboum & Sladek 1980), which leads to severe reduction in TPMT enzyme 
activity (‘slow metabolisers’). The resulting accumulation of 6-MP can cause severe 
myelosuppression (Lennard et al. 1993; McLeod et al. 2000) and maybe prevented by 
reducing the dose to 10% of the standard 6-MP dose. Genetic testing to assess the TPMT 
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activity status for each patients was introduced in the UKALL 2003 protocol (Medical 
Research Council 2009). Noticeably, there is a ‘translational time lag’ of over 20 years 
between discovery of inherited TPMT deficiency and introduction of routine genetic testing 
prior to treatment with 6-MP or other thiopurines. 
1.7 Aims and objectives of the thesis 
Having highlighted the lack of reliable data with regards to ADRs in hospitalised children and 
having described the emerging role of pharmacogenomics in reducing the occurrence of 
serious ADRs specific to the paediatric population, the aim of my thesis was to contribute to 
improved drug safety in paediatric patients by 
• Determining the incidence of ADRs in hospitalised children and identifying risk 
factors for the occurrence of ADRs in this population. Characterising those ADRs 
identified in terms of causality, reaction types and medication implicated. 
• Assessing the contribution of ADRs in hospitalised children to duration of hospital 
stay in order to estimate the economic burden of ADRs in children. 
• Examining the association between described genetic variants and cisplatin induced 
hearing loss in a UK paediatric cohort, an important example of a high impact ADRs.   
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2 Incidence, characteristics and risk factors of Adverse Drug 
Reactions in hospitalised children – a prospective observational 
cohort study of 6601 admissions 
2.1 Introduction 
Reducing the impact of paediatric ADRs needs precise estimates of the incidence and nature 
of ADRs.  A recent systematic review of 102 studies of ADRs in children by Smyth et al. (Smyth 
et al. 2012) showed that previous studies have differed widely in their definition of ADRs, 
clinical settings, and age range of children studied and a high proportion had major 
shortcomings in design and/or reporting. A large proportion did not report data on 
incidence, severity and causality of ADRs or drugs and reaction types implicated. Study sizes 
for the 21 prospective paediatric inpatient studies ranged from 81 to 3726 patients – 3/21 
of these studies were large (n>1000). Reported incidence rates for hospitalised children 
experiencing an ADR ranged from 0.6% to 16.8%. A recent prospective analysis of 3695 
patient-episodes in adults (Davies et al. 2009) reported an ADR incidence rate of 14.7% with 
estimated rates in earlier studies ranging from 0.86% (Simmons, Georgeson & Hill 1998) to 
37% (Van Kraaij et al. 1994) depending on study population, design and setting. 
Data on the drugs associated with ADRs were only available in 52 of 102 studies investigated 
in the systematic review by Smyth et al. and many did not report the associated clinical 
presentations. Although 70% of studies analysed in this systematic review referred to a 
causality assessment, less than one third reported this in detail. Of 34 studies which assessed 
the severity of ADRs, only 20 provided a reference for the assessment tool used, with 
proportions of severe reactions reported from 0 to 66.7%. Only 14 studies provided data on 
avoidability of ADRs and outcomes differed widely, with 7-98% of ADRs deemed 
definitely/possibly avoidable. Furthermore, few studies to date have investigated risk factors 
for ADRs in children. In the systematic review, female gender (10/19 studies), increasing 
number of drugs (16/17 studies), off-label use (3/3 studies), and oncological treatment (2 
studies) were identifiable risk factors (Bellis et al. 2013; Smyth et al. 2012).  The methodology 
of this study aimed to avoid these shortcomings and provide robust findings. 
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2.2 Aim  
The aim of this study was to determine the incidence of ADRs in paediatric medical and 
surgical inpatients, to characterise those ADRs identified in terms of type, medication 
implicated, causality, and severity, and to identify factors which increase the risk of ADRs.  
2.3 Methods  
2.3.1 Development of methods and author’s contribution 
This study was part of the wider ADRIC programme, planned by Prof Sir Munir Pirmohamed, 
Prof Anthony J Nunn, Prof Rosalind L Smyth, Prof Paula R Williamson, Prof Matthew Peak 
and Dr Mark A Turner who were also the senior investigators of this study.  
The contribution of the author of this thesis (ST) to this study, was to develop a workable 
methodology for identification, assessment and evaluation of ADRs. Methods based on 
those used by Gallagher et al. (Gallagher et al. 2012) and Davies et al. (Davies et al. 2009) 
were piloted. The most significant finding was time constraint. With three investigators, the 
same number as used by Gallagher et al. for their study, it was not possible to collect the 
target data identified by the senior investigators, and hence first attempts at conducting a 
pilot study had to be abandoned early, after incomplete data collection. This was somewhat 
surprising but could be partly explained by the following significant differences between this 
and the two studies cited above. In this study, ADRs were identified throughout the stay, in 
Gallagher et al.’s study only at one single time point, the time of admission. In contrast to 
Davies et al., patients in this study, who were admitted over the weekend were included and 
medication data were collected for all patients thought the stay rather than only for patients 
with ADRs with a random control sample of 1:10.  
To understand the impact and duration of the different steps involved, such as collection of 
patient data, collection of medication data, ADR identification, ADR evaluation, the author 
of this thesis conducted a step-by-step analysis with special consideration of the time 
involved. This analysis identified that the evaluation of suspected ADRs was one of the most 
time-consuming steps and could often only be completed after discharge. It was therefore 
decided to separate this step from the daily collection of data and prospective identification 
of ADRs by allocating study team members (research pharmacist, research nurse or the 
author of this thesis in regular rotation) to either the task of compiling ADR case reports or 
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collecting patient data and identifying potential ADRs as outlined below. Another outcome 
of the step-by-step analysis was that the study team felt, that there was a lot of redundancy 
of clinical information. When the author of this thesis analysed this aspect further in a 
sample of 24 suspected ADRs, it became apparent, that only a 4 of 26 suspected ADRs were 
identified from scrutinising the medical notes but these reactions were also identified from 
prescription chart review and/or review of the nursing notes. The majority of suspected 
ADRs, that is 21 of 26, were identified from the nursing notes, more than half, 14 of 26, from 
the prescription charts and 12 of 26 from review of observation charts. It was therefore 
decided to limit the time-consuming step of reviewing of medical notes as outlined below.  
Furthermore, the author of this thesis identified the exclusion of PICU as a necessary 
adaption for the final methodology. The implications of these steps are discussed under 
limitations. Primarily, the assessment of ADRs occurring in a PICU setting is far more complex 
and therefore requires different methodologies for detection compared to the rest of the 
study. Ideally, paediatric intensive care specialists – clinicians, pharmacists and nurses –  
should be part of the research team identifying and assessing ADRs in this environment. 
Secondarily the assessment of ADRs in patients admitted to PICU is more time consuming, 
owing to the inevitable complexity of the clinical background and management. 
The author of this thesis then also established that neither the Hallas’ avoidability tool  as 
used by Gallagher et al., nor any other available avoidability tool was suitable for this study 
and avoidability could therefore not be assessed. The implications of this step are discussed 
under limitations. 
In addition to the above, the author of this thesis was part of the study team that collected 
patient data, medication data and ADR details prospectively over one year as outlined 
below. From a practical point of view this meant daily visits to the hospital wards, in order 
to review and enter data prospectively into the study database using study laptops on. The 
author also compiled ADR case reports, assessed the causality of every ADR case (process 
outline below), oversaw the MeDRA coding and assessed all ADRs that had occurred prior to 
a patient being transferred to PICU or HDU, to evaluate their contribution to the patient 
being transferred to a higher level of care. Furthermore, the author of this thesis worked 
with the team of statisticians to provide the clinical context for the analysis as outlined 
below.  
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2.3.1 Study design and setting 
This was a prospective observational cohort study conducted over one year in a single 
secondary and tertiary paediatric referral centre, Alder Hey Children’s NHS Foundation Trust, 
which treats 200,000 children a year from the North West of England, North Wales, 
Shropshire and the Isle of Man. The Accident and Emergency department treats over 60,000 
children every year. There are 274 inpatient beds, including PICU. Although neonates were 
included in the study, the hospital does not have a designated neonatal intensive care unit 
(NICU), since a NICU exists in a nearby tertiary maternity centre. Any neonates requiring 
surgical management (including cardiac surgery) are transferred to Alder Hey, and cared for 
on PICU (if ventilated), the cardiac ward, or on the neonatal ward (surgical patients not 
requiring ventilation). 
2.3.2 Participants 
The study population comprised children aged between 0 and 16 years 11 months on 
admission, who were inpatients between 1st October 2009 and 30th September 2010. 
Extensive pilot work before the study established that the study team did not have the 
resources to carry out a detailed review of every inpatient every day. In 2008, a total of 
39,747 inpatient admissions were recorded (emergency admissions, elective admissions and 
day-case attendances); of those 10,943 stayed longer than 24 hrs and 5357 stayed longer 
than 48 hours. A pragmatic decision was thus made to include only those children who had 
been inpatients for >48 hours. Admissions included in this study were elective and 
emergency admissions of all paediatric medical and paediatric surgical specialities. 
Observations were carried out on 17 wards, including oncology wards and the high 
dependency unit (HDU). Patients were not observed whilst admitted to the paediatric 
intensive care unit (PICU), theatre, recovery or the department of radiology.  
2.3.3 Participant selection and data collection  
The established hospital database Meditech (MEDITECH 3.0 Health Care Information 
Systems (HCIS), Westwood, USA) was used for the recruitment of patients to the study. 
Electronic files containing a list of all children in the study population who met the inclusion 
criteria were automatically generated every 12 hours.  
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2.3.5 Data collection and handling 
Patients were identified by name, hospital number and admission number. Data were 
entered directly into the study database created for this study. The study database was 
stored securely on the Trust server. For the purpose for statistical analysis an anonymised 
copy of the database was created after completion of data entry. At study entry, the data 
set outlined in Table 2.1 was recorded.  
Table 2.1 Dataset recorded for each patient at study entry with format and source of data 
Data Source Format of entry into study data base 
Age* Meditech  Automatic download**  
Gender Meditech Automatic download** 
Weight (kg) Prescription chart, 
Observation chart, A&E 
documentation 
Manual entry 
Surface area (SA) m2 Prescription chart, medical 
notes 
Manual entry  
Drug allergies  Prescription chart(s), Medical 
notes, nursing notes  
Not known (tick box) or free text 
Date of Admission  Meditech Automatic download* 
Reason for admission  Medical notes, nursing notes Free text entry 
Past medical History Medical notes, nursing notes  Free text entry  
Medication History Medical notes, Prescription 
chart(s) 
Drug name, route, dose, frequency (drop 
down menu) 
Current Medication Prescription chart(s), 
Emergency department 
document 
Drug name, route, dose, frequency (drop 
down menu) 
*Data files containing a list of all children in the study population who met the inclusion criteria were 
automatically generated every 12 hours and imported into the study database. The files contained patient name, 
hospital number, admission number, DoB, age and date of admission.  
** Age was given as mm/dd up to one year, as yy/mm up to 6 years and as years from 6 years. 
Children who did not receive any medication during their admission were highlighted in the 
database (tick box “no medication”) to avoid misclassification. Any days of admission to PICU 
or HDU were also recorded in the study database. After discharge, patients with an oncology 
or haemato-oncology diagnosis and on-going medical treatment were highlighted through 
an additional entry in the database. Patients who had been admitted to theatre and had 
undergone general anaesthesia (GA) were identified through the hospital database 
Meditech and the date of admission to theatre was transferred into the study database 
through file import. For the duration of the hospital stay and within the study period, each 
child was followed up every 48 or 72 hours on weekdays and weekends respectively by one 
member of a multidisciplinary team of researchers comprising two research pharmacists, 
one research nurse, and a paediatrician (ST).  
  27 
2.3.5.1 Inclusion and exclusion of medicines 
Medicines were included in this study if they were prescribed and administration was 
recorded on the medical prescription sheet, the anaesthetic charts, the emergency 
department document, the prescription sheet for post-operative pain or the prescription 
sheet for opioids on the oncology ward. Suspected reactions to certain blood products, total 
parental nutrition and intravenous hydration fluids were excluded from this study (Table 
2.3). 
2.3.5.2 Data of medicinal products and suspected ADRs  
At each visit the following details were recorded for all medication administered on the 
ward: Drug name, route of administration, dose and daily frequency. In addition, children 
were reviewed for occurrence of new symptoms or those that had worsened and for 
abnormal results, that may have indicated the occurrence of an ADR, taking into account the 
case history, the ADR profiles of medication and the temporal relationship between drug 
exposure and reaction. Data reviewed to detect new or worsening symptoms or abnormal 
results are summarised below. 
Table 2.2 Data used to identify reactions suspected to be an ADR and their sources 
Type of data Source  
Medical notes* Handwritten paper records  
Emergency department document** Handwritten paper records 
Nursing notes  Electronic (Meditech) 
Prescription charts including specialist prescription charts such as 
pain charts and  chemotherapy prescription charts   
Handwritten paper records  
Clinical charts e.g. observation chart, fluid balance chart Handwritten paper records 
Care pathways e.g. for children admitted with diabetic ketoacidosis 
or asthma; post-operative pathways 
Handwritten paper records 
Imaging results  Electronic report (Meditech) 
Laboratory results  Electronic reports (Meditech)  
*Medical notes were only reviewed at study entry and to assess suspected ADRs.                      
** If the patient had been admitted via the accident and emergency department. 
Key reference used, were the Summary of Product Characteristics (SmPC) in the electronic 
Medicines Compendium (eMC)(DataPharm Communications Ltd. 2010) or the British 
National Formulary for Children (BNFC) (Paediatric Formulary Committee 2008/2009). 
Reactions suspected to be an ADR were highlighted and then followed up separately (2.3.7). 
This two-step approach was taken because detailed ADR assessments are more time 
consuming and relevant information (e.g. results of investigations, response to withdrawal 
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or reduction of medicine) was often only available at time of or after discharge. Some 
highlighted reactions could not be assessed because of missing or conflicting information, 
for example if the nursing notes stated bowels opened but the clinical chart for the same 
day stated bowels not opened.  
Members of the study team, consisting of research nurses (KB and HM), research 
pharmacists (JB, LB and JC) and a paediatrician (ST) took it in turns to collect data and follow 
up ADRs. However, KB left the study team and was replaced by HM. JB and ST were part of 
the team throughout and LB and JC joined the study team once data collection had 
commenced. 
2.3.6 ADR definition  
In this study the following definition of Edwards and Aronson (Diez 1998; Edwards & Aronson 
2000) was used: An ADR is “an appreciably harmful or unpleasant reaction, resulting from 
an intervention related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dose 
regimen, or withdrawal of the product.” Prescribing or administration errors as well as 
accidental or deliberate overdoses were thus not considered ADRs in this study.  
ADR cases in this study were defined as suspected reactions to any systemic or topical 
medicinal product administered in hospital and presenting after admission to the ward or in 
the accident and emergency department prior to admission to the ward. This included 
reactions to medicinal products administered in PICU, theatre, recovery, the department of 
radiology, provided the reaction became apparent after transfer to a ward. Reactions to a 
medicinal product had been started prior to admission were included if (1) it was continued 
in hospital and (2) the reaction was not apparent on admission 
.
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Table 2.3 List of drug groups or non-medicinal products which were not considered in this study (excluded) and exceptions (included) with rationale. 
 
 
Excluded Included Rationale 
Topical anaesthetics Lidocaine 2·5%, prilocaine 2·5% 
cream (EMLA®) or tetracaine 4% 
gel (Ametop®) 
LAT gel (lidocaine 4% & adrenaline 0·1% & tetracaine 
0·5% gel) 
Topical anaesthetics were not always prescribed on the 
medication prescription charts.  
Ranitidine Ranitidine added to TPN. Ranitidine administered otherwise Ranitidine added to TPN is not prescribed on the regular 
medication prescription chart.  
Heparin Heparin administered as 
intermittent intravenous heparin 
flush. 
Intermittent intravenous injection other than 
heparin flush, heparin administered as continuous 
intravenous infusion or as subcutaneous injection. 
Administration of Heparin administered as intermittent iv 
heparin flush was not reliably recorded. 
Total parenteral 
nutrition (TPN) 
Total parenteral nutrition (TPN) N/A The individualised nature of TPN and iv fluid prescribing 
means that a large amount of additional data would need 
be collected for every patient.  Intravenous hydration 
fluids 
Intravenous hydration fluids. Any drugs added to intravenous fluids 
Rectal washouts Rectal washouts with Sodium 
Chloride 0·9%. 
N/A Administration was not reliably recorded. 




Fresh Frozen Plasma 
Antithrombin III Concentrate; Dried Prothrombin 
Complex; Drotrecogin Alfa (activated); Factor VIIa 
(recombinant) 
Factor VIII Fraction, dried; Factor VIII Inhibitor ; By-
passing Fraction; Factor IX Fraction, Dried; Factor XIII 
Fraction, Dried; Protein C Concentrate 
The excluded products are not medicines. They are 
obtained from the transfusion service. 
The included products are listed in the BNF and some were 
under intensive surveillance by the MHRA 
Oxygen therapy Oxygen therapy N/A Oxygen is not prescribed. It would have been difficult to 
obtain and record data of the amount of oxygen 
administered 
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2.3.7 Assessment of ADRs including causality 
Each reaction suspected to be an ADR was followed up with an assessment by one research 
team member who compiled an ADR case report. This report included a detailed description 
of the suspected reaction and its time frame, results of any relevant investigations, details 
of the clinical management and the outcome for the patient.  
2.3.7.1 Causality assessment  
Each ADR case report was then assessed independently by (1) a research nurse, (2) a 
research pharmacist and (3) a paediatrician (ST) using the Liverpool adverse drug reaction 
causality assessment tool (Gallagher et al. 2011) as unlikely, possible, probable or definite . 
Outcome reporting was based on consensus agreement between the three assessors, if 
agreement could not be achieved, the case was referred to a panel of two senior 
investigators who reached a joint consensus about the causality outcome. For ADRs with a 
high or uncertain probability that the reaction is due to an underlying disease, the causality 
outcome is “possible” unless objective evidence of the causal ADR mechanism is available. 
For the analysis of results and incidence calculation we considered probable and definite 
ADRs as they were deemed to have a low probability of the underlying disease causing the 
reaction. 
2.3.7.2 Coding of reaction type 
To standardise reaction types and facilitate analysis of results, all possible, probable and 
definite ADRs were coded using the Medical Dictionary for Regulatory Activities terminology 
(MedDRA). MedDRA is the international medical terminology developed under the auspices 
of the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) (International Federation of 
Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland). 
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*Unassessable refers to situations where the medicine is administered on one occasion (e.g. Vaccine), the patient receives intermittent therapy (e.g. Chemotherapy), or is on medication which 
cannot be stopped (e.g. Immunosuppressants). **Examples of objective evidence: positive laboratory investigations, supra-therapeutic drug levels, good evidence of dose-dependent 
relationship with toxicity in the patient 
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2.3.7.3 Assessment of severity  
Severity of ADRs was assessed by the researcher compiling the case report using a modified 
form of the Hartwig scale (Hartwig, Siegel & Schneider 1992).  In addition, all ADRs that 
occurred prior to a patient’s admission to PICU or HDU were also assessed by a paediatrician 
(ST) and, if required, reviewed by a panel of two senior investigators in order to evaluate 
their contribution to the patient being transferred to a higher level of care (Hartwig level 4). 
Reactions classified as Level 4 and above were considered severe. 
Table 2.4 Modified Hartwig ADR Severity Assessment Scale (Hartwig, Siegel & Schneider 
1992) 
Severity level                                    Level definition 
1 Required no change in treatment 
2 Drug dosing or frequency changed 
3 Required treatment, or drug administration discontinued 
4 Result in patient transfer to higher level of care 
5 Caused permanent harm to patient or significant haemodynamic instability 
6 Directly or indirectly resulted in patient death 
 
2.3.7.4 Contribution to duration of stay 
ADRs were assessed for their potential contribution to the duration of stay. This is presented 
and discussed in chapter 3. 
2.3.8 Incidence 
The incidence of ADRs was calculated to describe (1) the burden of inpatient ADRs to the 
hospital (incidence) and (2) the burden of paediatric inpatient ADRs to the patient (incidence 
per child). It was calculated by dividing the number of admissions with at least one ADR by 
the total number of admissions regardless of drug exposure and the number of children with 
at least one ADR by the total number of children respectively.  
2.3.9 Outcomes 
The observed outcome was the occurrence of an ADR. For the risk factor analysis time from 
admission to first ADR was calculated in days. For patients admitted to PICU this was time to 
first ADR prior to PICU admission.  
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ADRs occurring after discharge from PICU were included in the overall count of events, but 
time from admission to PICU was censored for the risk factor analysis.  
2.3.10 Risk factors 
Age, gender, number of medicines, admission to theatre and oncology patient status were 
assessed as risk factors. Age on admission (in years) was treated as a continuous variable 
and gender as a categorical variable. Both were treated as time-invariant risk factors in the 
multivariate model. The number of medicines count refers to the daily number of medicines 
administered to the patient on the ward. As this risk factor was counted daily throughout 
the admission period, it was treated as a continuous, time-varying covariate in the 
multivariate model. The factor “admission to theatre” was considered to be present from 
day of (first) undergoing a general anaesthetic (GA) until discharge from hospital. This risk 
factor was treated as a binary, time-varying variable in the multivariate model that takes the 
value zero on days up to an admission to theatre and unity thereafter for the remaining days 
of a patient’s admission. Oncology patient status, had emerged as a significant risk factor for 
ADRs leading to hospital admission and was therefore considered as risk factor in this study. 
It was considered a binary, time invariant factor to distinguish oncology and non-oncology 
patients.  
Off-label and unlicensed medicine use in this study population was investigated and 
analysed separately (Bellis et al. 2013) 
2.3.11 Statistical methods 
The analysis plan for for this study was designed by JJK, EC, LC and PW. Statistical analysis 
was carried out by EC, who used the statistical software package R (version 2.13.2). The role 
of the author of this thesis was to provide the clinical context for example by explaining the 
data collection process and limitations, to ensure data quality and finally to provide clinical 
interpretation of the data.    
A time-to-event model of analysis model was chosen to allow inclusion of patients into the 
analysis, who were admitted to PICU during their hospital stay, where ADRs were not 
observed. Time-to-event analysis models allow this through inclusion of censored data.  
A two-sided significance level of 0.05 (5%) was used throughout the analysis.  
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A univariate analysis on data collected for each patient during their first admission was used 
to assess the affected patient population. A univariate analysis of the risk factors was 
performed to explore the effect that patient characteristics has on the likelihood of an ADR. 
Kaplan Meier (KM) curves were produced for each level of a categorical prognostic factor 
and ADR-free survival data compared between groups using a log-rank test (extending to a 
log rank test for trend when appropriate). However, comparison of KM curves can only 
conclude that that a difference between survival curves exists. In contrast, a regression 
model of analysis allows to measure the risk arising from individual clinical factors. The most 
commonly used multivariate approach for this is the Cox regression model, which relies on 
the assumption of proportional hazards between survival curves. Both a single event and a 
multi event Cox proportional hazards regression model was fitted to the data. Results for 
both models are given in terms of the hazard ratio (HR) together with accompanying 95% 
confidence intervals (95% CI). Due to their clinical importance, all the risk factor variables 
are included in both models. 
The proportional hazards assumption for each covariate was investigated using log 
cumulative hazard plots and Schoenfeld residual plots. The assumption was also tested for 
significant violations through incorporation of a time-dependent covariate.  
Deviance residuals were plotted against the linear predictor to look for mis-modelling of the 
data and empirical validation of the model was done using a data splitting technique to 
assess model accuracy.   
2.3.12 Missing data 
Patients with missing prescription details for the entire duration of the admission could not 
be assessed for ADRs and were therefore withdrawn from the study. Patients with partially 
missing prescription details (e.g. prescription details for day of discharge) or missing clinical 
observations were assessed on a case-by-case basis by the research team and a rationale for 
inclusion or withdrawal was recorded for each case. Patients were only included if it was 
considered unlikely that the missing data would have led to missing an ADR.  Furthermore, 
any potentially missed ADRs towards the end of the stay are unlikely to have had an impact 
on the risk factor analysis as time to first ADR was the observed outcome. 
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2.3.14 Potential sources of bias 
Investigations were based on clinical indication and observations dependent on 
documentation by the clinical team. Hypertension could e.g. only be observed if a child’s 
blood pressure was monitored for clinical reasons. 
Only ADRs observed between 1st October 2009 and 30th September 2010 were recorded. 
Patients admitted between 28th and 30th September 2009 or discharged after 30th 
September 2009 who experienced an ADR before 1st October 2009 or after 30th September 
2010 were counted as admissions without ADR in this study. Consequently, there are 180 
admissions that lie outside the observation period where an ADR may have occurred that 
has not been recorded. 
2.3.15 Ethical considerations 
This study used routinely collected clinical data in an anonymised format. The Chair of 
Liverpool Paediatric Local Research Ethics Committee (LREC) therefore declared that this 
study did not require individual patient consent or review by an Ethics Committee. 
2.3.16 Funding  
This study was funded by the National Institute of Health Research (NIHR) as part of a 
research programme grant awarded to the University of Liverpool and Alder Hey Children’s 
Hospital to investigate Adverse Drug Reactions in Children (ADRIC). 
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2.4 Results  
2.4.1 Participants and descriptive data 
6825 eligible admissions were identified. 181 (2.7%) admissions could not be included due 
to missing data. Forty-three patients spent their entire admission on PICU and were thus 
excluded. Consequently 6601 admissions of 5118 children were included in the study; of 
these, 827 were also admitted to PICU with 45.2% being cardiology or cardiothoracic 
patients. The median duration of follow up time across admissions was 5 days (IQR 3.8 days, 
range 2 - 280 days). The median age on admission was 3.4 years (IQR 0.6-10.7); 2297 (44.8%) 
were female. 4284 (83.7%) of children had one admission and 834 children had more than 
one admission.  2856 children (55.8%) underwent at least one GA during 3265 admissions 
(49.4%); 114 children (2.2%) were oncology patients. 126 children (2.4%) did not receive any 
medicines during 150 admissions (2.3%). In 98.7% of admissions with medicine, more than 
one medicine was administered and 98.5% of children who received medicines during their 
admission(s), received more than one medicine in at least one admission (4919/4992). The 
median daily number of medicines administered was 3 (IQR 1-5). 
2.4.2 Causality and severity of ADRs 
3568 suspected reactions were assessed and a total of 2934 ADR case reports completed. 
The review process is outlined in Figure 2.2. After causality assessment, 213 (7.3%) of the 
suspected ADRs were deemed definite, 1233 (42.0%) probable, 896 (30.5%) possible, and 
592 (20.2%) unlikely. Consensus was reached independently in 1805 cases (61.5%) and by 
panel decision in 1128 cases (38.5%). All definite and probable ADRs were included in the 
further analysis (total number 1446). 0.8% of ADRs were severe and required patient 
transfer to a higher level of care. One patient sustained permanent harm (peripheral 
neuropathy due to vincristine). No ADR resulted in death. Details of all severe reactions by 
reaction type and associated drugs are listed in Table 2.6.
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Figure 2.2 Summary of review process of reactions highlighted during patient visits  
3325 suspected reactions
340 reactions could not be assessed
67.3% (229/340) Not enough information
14.8% (47/340)   Prescription/anaesthetic details missing
8.8%  (30/340)   Conflicting information  
0.8% (3/340)      Problem with laboratory sample
2934 ADR case reports*
2985 suspected reactions*
ADR assessment including causality assessment  
3568 suspected reactions
243 reactions  did not meet inclusion criteria
43.6% (106/243) Reactions started whilst patient admitted to PICU
30.9 % (75/243)  Reactions started prior to admission to hospital
15.2% (37/243)   Reaction is not an ADR (e.g. prescription error)
10.2% (25/243)   Reaction started whilst patient was in theatre or recovery
*Different suspected reaction types highlighted in the same patient due to the same medication(s) would have 
been reported as one ADR case e.g. A patient with respiratory depression and bradycardia = 2 suspected 
reactions highlighted and assessed in one ADR case report  
 
Table 2.5 Assessment of Severity using a modified Hartwig scale (2.3.7.3) 
Severity 
level 
Description Number of ADRs at each 
severity level* 
n % 
1 Required no change in treatment 322 22.3% 
2 Drug dosing or frequency changed 66 4.6% 
3 Required treatment, or drug administration discontinued 1046 72.3% 
4 Resulted in patient transfer to higher level of care 12 0.8% 
5 Caused permanent harm to patient or significant 
haemodynamic instability 
1 0.1% 
6 Directly or indirectly resulted in patient death 0 0% 
*Denominator was the total number of probable or definite ADRs  
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Table 2.6 Severe reactions (Hartwig scale ≥ 4) by reaction type and medication implicated  
Severity 
level 





to PICU or 
HDU 
(count) 
4 Cardiac failure (1) Bisoprolol (1), Carvedilol (1) HDU (1) 
Sedation withdrawal (1) Fentanyl (1), Midazolam (1),  
Promethazine (1) , Chloral hydrate (1) 
PICU (1) 
Raised INR and haemorrhage (1)  Warfarin (1) HDU (1) 
Pulmonary oedema (1) Diazoxide (1) HDU (1) 
Respiratory depression (5) Fentanyl (4), Ketamine (2), Midazolam (1), PICU (3)*, 
HDU (2)  
Respiratory arrest (2) Fentanyl (2), Sevoflurane (1), Isoflurane (1), 
Ketamine (1) 
PICU (1),  
HDU (1) 
5 Peripheral neuropathy (1) Vincristine (1) N/A 
* ADR was not the only factor leading to PICU admission; other, clinical factors may also have contributed  
 
2.4.3 Incidence and Risk factor analysis 
The overall incidence of definite and probable ADRs based on admissions was 15.9% (95% CI 
15.0-16.8), and 17.7% when based on numbers of patients (95% CI 16.7-18.8). The ADR 
incidence for patients with only one admission was 14.8% (95% CI 13.7-15.9). For patients 
with more than one admission, the incidence per admission was 18.0% (95% CI 13.7-15.9) 
but 32.7% per patient (95% CI 29.6-35.9).  
Only first admissions were included in the univariate and multivariate analysis (Figure 2.3). 
Results of the univariate analysis are shown in  
Table 2.7. Multivariate risk factor analysis of first admissions is shown in Table 2.8 and 
indicated that the risk of an ADR was associated with a GA, more than one medicine, being 
an oncology patient and age.  
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Figure 2.3 Flowchart outlining the number of admissions included in the univariate and 
multivariate risk factor analysis 
• 769 patients with >1 admission 
318  ADRs = ‘multi admission’
• 118 patients had >1 ADR during first admission 
145 ADRs = ‘multi event’ during first admission
1446 ADRs
6601 Admission; 5118 Patients 
• 151 Admissions without drug exposure
• 129 ADRs with identical start date 
>1 ADR/day during same admission = 1 ADR event
• PICU from day 1 => censored from day one
356 patients; 43 ADRs
• PICU after day 1 => censored from day of PICU admission
117 ADRs
1157 ADRs
6094 Admission; 4724 Patients 
694 ADRs
694 Patients with at least one ADR
4030 Patients without ADR
 
 
Table 2.7 Univariate analysis by categorical time invariant risk factor 
Covariate  N of Patients  (%) 
(total N = 4724) 
N of patients with 
ADR* (%) 
p-value 
Gender Male 2602 (55.1%) 382 (14.7%) 0.900 
 Female 2122 (44.9%) 312 (14.7%)  
Age on admission <1 year 1369 (29.0%) 78   (5.7%) <0.001 
 1-5 years 1259 (26.6%) 155 (12.3%)  
 5-11 years 1105 (23.4%) 231 (20.9%) 
 >11 years 991   (21.0%) 230 (23.2%) 
Oncology Yes 103   (2.2%) 45   (43.7%) <0.001 
 No 4621 (97.8%) 649 (14.4%)  
* Only the first ADR was included in this analysis 
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Table 2.8 Risk factors for ADRs assessed by multivariate analysis 
Covariate  HR 95% CI p-value 
Gender Female 1  0.301 
Male 0.93 (0.8-1.08)  
Age on admission *  1.06 (1.04-1.07 <0.001 
Number of drugs  1.25 (1.22-1.28) <0.001 
Received a GA No 1  <0.001 
 Yes 6.38 (5.30-7.68)  
Oncology No 1  <0.001 
 Yes 1.89 (1.36-2.63  
HR = hazard ratio; CI = confidence interval ; * in years 
 
2.4.4 Reaction types, drug classes implicated in ADRs  
Reaction types are listed in Table 2.9. The three most common reaction types together 
(nausea and/or vomiting, pruritus and constipation) accounted for 54.8% of all ADRs. Drug 
classes implicated in ADRs are listed in Table 2.10. The three most common drug classes 
were opioid analgesics, drugs used during GA and cytotoxic drugs and together accounted 
for 67.1% of all drugs implicated in ADRs. 
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Reaction following GA** 
(n=845) 
 N % N % 
Nausea and/or vomiting  400 27.5% 295 73.8% 
Pruritus 243 16.7% 232 95.5% 
Constipation 155 10.6% 107 69.0% 
Diarrhoea (9/88 with vomiting) 88 6.0% 0 0.0% 
Somnolence (without cardio-respiratory  
symptoms) 
50 3.4% 34 68.0% 
Respiratory depression (41)/ arrest (3) 44 3.0% 43 97.7% 
Candidiasis  41 2.8% 0 0.0% 
Urinary retention  40 2.7% 37 92.5% 
Rash  31 2.1% 3 9.7% 
Hypokalaemia 25 1.7% 0 0.0% 
Hypotension  22 1.5% 9 40.9% 
Hepatotoxicity (in 12/18 transaminases 
increased only) 
18 1.2% 1 5.6% 
Stomatitis 16 1.1% 0 0.0% 
Myoclonus 15 1.0% 14 93.3% 
Pancytopenia 13 <1% 0 0.0% 
Hyperglycaemia 12 <1% 0 0.0% 
Hypertension 11 <1% 2 18.2% 
Allergic reactions  10 <1% 3 30.0% 
Pain (4/10 pain in jaw, 2/10 back pain) 10 <1% 0 0.0% 
Other reactions (occurred < 10 times) 213 14.6% 65 30.5% 
* If the same patient experienced 2 types of reactions to the same medication(s) at the same time this would 
have been reported as one ADR case but will be listed here as 2 reaction types e.g. A patient with respiratory 
depression and bradycardia = one ADR case, but listed as two reactions. **Reaction occurred post theatre AND 
drugs given in theatre and/or used in post-operative pain management were implicated. 
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Table 2.10 Drug groups implicated in ADRs by frequency with associated reaction types 
Drug Group 
(N of ADR cases) 
Total N of drugs 
(% of total) 
Drugs (N) 
  
ADR type* (N) 
 
Opioid analgesics (688)        844 (27·9%) Morphine (426), Fentanyl (267), Codeine  (144), Dihydrocodeine (4), 





Pruritus (198), Nausea or Vomiting (186), Constipation (143) 
Respiratory arrest/ depression (3/37), Somnolence without cardio-
respiratory symptoms (37), Urinary retention (28), Myoclonus (13), 
Hallucination (8), Rash (4), Bradycardia (3), Dizziness (3), Drug 
withdrawal syndrome (3), Ileus (3), Agitation (2), Delayed recovery 
from anaesthesia (2), Flushing (2), Visual disturbance (2), other ** 
(11)  
Drugs used in GA   
(322) 
[excluding opiate analgesics 
other than remifentanyl] 
779 (25·8%) Sevoflurane (253), Propofol (200), Nitrous oxide (131), Remifentanil 
(83), Desflurane (54), Isoflurane (38), Ketamine (6), Atracurium (4), 
Rocuronium (4), Thiopental (4), Atropine (1), Vecuronium (1) 
Nausea or vomiting (266), Urinary retention (21), Respiratory arrest 
or depression (2/6), Delayed recovery from anaesthesia (5), 
Flushing (4), Bradycardia (3), Allergic reaction (3), Hypotension(3), 
Pruritus (2), other ** (7) 
Cytotoxic drugs and drugs used 
for cytotoxic induced side 
effects (179)                                                      
405 (13·4%) Vincristine (70), Etoposide (56), Cyclophosphamide (46), Cytarabine 
(41), Methotrexate (31), Doxorubicin (22), Ifosfamide (21), Mesna 
(15), Daunorubicin (13), Carboplatin (12), Cisplatin (12), Melphalan 
(11), Busulfan (7), Asparaginase (6), Fludarabine (6), Clofarabine (5), 
Actinomycin D(5), Allopurinol (4), Mitoxantrone (4), Rasburicase (4), 
Idarubicin (3), Thiotepa (3), Amsacrine (2), Temozolomide (2), 
Cladribine (1), Gemcitabine (1), Irinotecan (1), Tretinoin (1) 
Nausea or vomiting (81), Stomatitis (16), Pancytopenia (13), 
Diarrhoea and vomiting (9), Diarrhoea without vomiting (9), 
Hepatotoxicity (11; 8 increased transaminases only), Febrile 
neutropenia (6), Rash (6), Pain in jaw (3), Constipation (3), Pain 
other than jaw (2), Headache (2), Hyperglycaemia (3), Oral 
candidiasis (3), other **(14) 
 
Antibiotics (162) 319 (10·6%) Cefotaxime (56), Metronidazole (29), Gentamicin (29), Piperacillin and 
Tazobactam (28), Cefuroxime (18), Teicoplanin (19),  Cefalexin (17), 
Ciprofloxacin (16), Flucloxacillin (15), Co-amoxiclav (16), Ceftazidime 
(13), Rifampicin (10),  Amoxicillin (8), Clarithromycin (7), Vancomycin 
(7), Penicillin V (5), Benzylpenicillin (4), Meropenem (4), Amikacin (3), 
Co-trimoxazole (3), Tobramycin (3), Trimethoprim (3), Clindamycin (2), 
Cefradine (1) , Ceftriaxone (1) 
Diarrhoea (66), Candidiasis (38) Rash (16), Nausea or vomiting (8), 
Clostridium difficile colitis (7), Colonisation with Candida (4), 
Transaminases increased (4), Anaphylactic reaction (2), Angioedema 
(2), Flushing (2), Hepatotoxicity (3), Pruritus (2), other** (8) 
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Drug Group 
(N of ADR cases) 
Total N of drugs 
(% of total) 
Drugs (N) 
  
ADR type* (N) 
 
Drugs used in epidurals, 
regional anaesthetics and IV 
drugs used in post- operative 
pain management other than 
opioids (188) 
195 (6·4%) Fentanyl & Levobupivicaine (116), Ketamine (36), Clonidine & 
Levobupivicaine (25), Levobupivacaine (11), Clonidine (7) 
Pruritus (52), Nausea and/or Vomiting (35), Constipation (24), 
Urinary retention (15), Somnolence without cardio-respiratory 
symptoms (11), Respiratory depression/arrest (8/1), Hypotension 
(7), Paraesthesia (6), Bradycardia (4), Myoclonus (3), Hypoaesthesia 
(2), Visual disturbance (2), Hallucination (2), Hypertension (2), 
Urinary incontinence (2), other **(12) 
Corticosteroids (51) 62 (2·05%) Dexamethasone (24), Methylprednisolone (14), Prednisolone (14), 
Hydrocortisone (8), Beclomethasone (1), Fludrocortisone (1) 
Hyperglycaemia (13), Hypertension (8), Candidiasis (9), Fluid 
retention 
(2), Gastritis (2), other** (17) 
Bronchodilators (31) 58 (1·92%) Salbutamol (35), Aminophylline (21), Ipratropium (2) 
  
Hypokalaemia (15), Nausea and/or vomiting (7), Tremor (4), 
Tachycardia (2), other ** (3) 
Antiemetics (50) 55 (1·82%) Ondansetron (51), Levomepromazine (3), Cyclizine (1) Constipation (45), Disorientation (2), other** (4) 
Antiepileptic drugs (45) 49 (1·62%) Midazolam (35), Pregabalin (4), Carbamazepine (3), Diazepam (3) 
Gabapentin (2), Lorazepam (1) Valproate (1) 
Nausea and/or vomiting (24), Somnolence without cardio-
respiratory symptoms (6), Abnormal behaviour (2), Constipation (2), 
Delayed recovery from anaesthesia (2), Respiratory depression (2), 
other** (7) 
Diuretics (28) 41 (1·36%) Furosemide (30), Spironolactone (8), Metolazone (2), Chlorothiazide 
(1)  
Hyponatraemia (9), Hypokalaemia (8), Hypotension (3), 
Hypomagnesaemia (4), other** (5) 
Drugs affecting the immune 
respones (supression and 
modulation) + cytokine 
modulators (31) 
34 (1·12%) Alemtuzumab (11), Ciclosporin (7) Adesleukin (5), Rabbit anti-human 
thymocyte immunoglobulin (3), Tacrolimus (3), Rituximab (2), 
Azathioprine (1), Mycophenolate (1) Tocilizumab (1) 
Pyrexia (4), Candidiasis (4), Infusion associated reaction (3), 
Stomatitis (3), Oedema (2), Pruritus (2), Vomiting (2), other** (11) 
 
Drugs affecting the 
cardiovascular system (23)  
27 (0·89%) Captopril (10), Lisinopril (4), Amlodipine (4), Milrinone (3), Bisoprolol 
(1),  Dinoprostone (1), Enalapril (1), Hydralazine (1), Isoprenaline (1), 
Carvedilol (1) 
Hypotension (11), Hyperglycaemia and Glycosuria (3), other**(9) 
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Drug Group 
(N of ADR cases) 
Total N of drugs 
(% of total) 
Drugs (N) 
  
ADR type* (N) 
 
NSAIDS (+ aspirin) (24)  24 (0·79%) 
  
Diclofenac (15), Ibuprofen (5), Naproxen (2), Aspirin (2) Nausea and/or vomiting (11), Haematemesis (3), Other 
gastrointestinal bleed (2), Constipation (2), other** (5) 
Laxatives (20) 22 (0·73%) Lactulose (12), Macrogol (6), Docusate (3), Sennoside (1) Diarrhoea (17), Abdominal pain (2) 
Vomiting (1) 
Antifungals and Antivirals (20) 21 (0·69%) Amphotericin (7), Aciclovir (5), Fluconazole (4), Voriconazole(2), 
Itraconazole (1), Miconazole (1), Ribivarin (1) 
Diarrhoea (8), Hepatotoxicity (3), 
Hypokalaemia (3), other** (5) 
Drugs used in diabetes and 
hypoglycaemia (13) 
16 (0·53%) Insulin (4), Insulin aspart (4), Insulin detemir (4), Diazoxide (3), 
Glucagon (1) 
Hypoglycaemia (7), Fluid overload (2), Hypokalaemia (2), other ** 
Other (69) 73 (2·41%) - - 
* If the same patient experienced 2 types of reaction to the same medication at the same time this would have been reported as one ADR case but will be listed here as 2 ADR types 






To our knowledge, this is the largest, prospective paediatric in-hospital study investigating 
ADRs. The study population represents a wide range of paediatric medical and surgical 
specialities, given the nature of the hospital as a regional centre. The methodology included 
causality and severity assessments using validated tools. An avoidability assessment was not 
undertaken because of the lack of appropriate tools and imperfect definitions of 
preventability as highlighted recently by Ferner and Aronson (Ferner & Aronson 2010). The 
most frequently used assessment tools were Schumock and Thornton (Schumock & 
Thornton 1992) and Hallas (Hallas et al. 1990) which are based on appropriateness of 
prescribing or treatment choice. These tools might be used successfully to improve 
prescribing practice in specific clinical circumstances. However, they become problematic 
when treatment is guided by multiple sources of tertiary paediatric specialist advice such as 
in this study. 
2.5.1 Incidence 
In a prospective, observational, paediatric, multicentre cohort study of 1278 patients (1340 
admissions), Rashed at al. reported an overall ADR incidence of 16.5% (95% CI, 14.5-18.7%) 
per patient (Rashed et al. 2012). Davies et al. conducted a comparable study in adults and 
observed an incidence of 14.7% per episode (admission) and 15.8% per patient (Davies et al. 
2009). However, both Rashed and Davies used the Naranjo algorithm (Naranjo, Busto & 
Sellers 1981) for causality assessment and included possible, probable and define ADRs in 
their calculations. In this analysis, only probable and definite ADRs were included, as these 
have a low probability of the underlying disease, or other co-morbidities, causing the 
reaction. Had possible ADRs been included, the overall ADR incidence rate would have been 
more than 25% per child (data not shown) which is much higher than that reported in adults. 
One possible explanation is, that many common medicines have not been tested properly 
or at all in infants and children.    
2.5.2 Severity  
Although less than 1% of reactions in this study were classified as severe, this does not take 
into account what impact an ADR might have on the child and/or carer. For instance, a 
teenage patient is likely to feel very distressed about having to be catheterised because of 




our study was vomiting, mainly observed in post-operative patients. Vomiting is a common 
and non-specific symptom in children and thus unlikely to be regarded as being particularly 
significant by clinicians. However, Diez reported that parents placed a very high value on the 
distress caused by post-operative vomiting (Diez 1998) In addition, parents of children 
included in this study reported that suspected ADRs cause them concern, irrespective of the 
“medical” severity of the suspected reaction. On the other hand, parents of children treated 
on the oncology unit valued the proactive explanations of ADRs given by clinicians, 
suggesting that this aspect should form part of the preoperative discussion (Arnott et al. 
2012). 
2.5.3 Risk factors for ADRs 
This study confirmed similar risk factors for ADRs to those reported previously, including 
increasing age, oncology treatment, and number of drugs (Gallagher et al. 2012; Rashed et 
al. 2011) . It is not entirely clear why ADR risk increased with age, but is likely to be due to 
many factors including lack of detection and the inability of a younger child to effectively 
communicate their symptoms (e.g. nausea, pain, hallucinations); acceptance of some 
common clinical manifestations such as vomiting and loose stools as being “normal” in 
younger children; and reaction types such as pruritus being mistaken for “unsettledness” in 
an infant.  
Most previous paediatric inpatient studies were carried out in general paediatric settings 
(Smyth et al. 2012) in which only a small number of patients, if any, will have undergone GAs 
thus underrepresenting drugs used in paediatric peri- and post-operative management. 
Rashed et al. who conducted their multicentre study on general medical wards, reported 
that anaesthetics, which accounted for only 1% of all prescriptions, were amongst the drugs 
most commonly implicated in ADRs (Rashed et al. 2011). In the two previous inpatient 
studies investigating paediatric surgical patients and providing medication details, opiate 
analgesics were amongst the two most commonly implicated drugs. However, data on drugs 
used in GAs were not reported, perhaps because they were not specifically investigated 
(Farrokhi et al. 2009; Turner et al. 1999). The differences in this study population, which 
included a large number of surgical patients (but not those admitted to PICU immediately 
post-operatively), are also reflected in the spectrum and severity of common reaction types 
observed. Some reaction types such as urinary retention and respiratory depression/arrest 




study occurred in post-operative patients and led to transfer to HDU or PICU (Table 2.6).  
Notably, the risk of experiencing an ADR in patients undergoing a procedure under GA has 
not been assessed previously.  
2.5.4 Type of reactions and drug groups implicated  
The most commonly implicated drug groups were opioid analgesics and drugs used in GA, 
which together comprised 53.7% of all drugs implicated in ADRs in this study. Pruritus, 
respiratory depression, and urinary retention occurred almost exclusively in the post-
anaesthetic setting. In over two-thirds of patients with nausea/vomiting, constipation, or 
somnolence, which together were contributing 41.5% of all reactions, drugs given during the 
anaesthetic and/or used in post-operative pain management were implicated. Morphine is 
one the most commonly used opioids in perioperative pain management in children, but 
there is significant inter-individual variability in analgesic response. This is partly explained 
by clinical factors such as age, gender, type and duration of surgery. However, there are also 
known ethic differences such higher frequency of opioid related ADRs in children of 
Caucasian origin (Sadhasivam et al. 2012) and there is an emerging body of evidence that 
genetic variability may explain differences in pharmacokinetics of morphine and other 
opioids in children (Fukuda et al. 2013; Venkatasubramanian et al. 2014) as well as the risk 
of morphine induced ADRs (Chidambaran et al. 2015; Chidambaran et al. 2016). Although 
these are very interesting findings, they are still a long way from becoming clinically relevant 
in the management of ADRs. The question at hand is, whether and how the post-operatively 
occurring reactions, could have been prevented. A focussed assessment of the 
preventability/avoidability of post-operative reactions by reaction type would provide much 
needed information in this area. Post-operative nausea and vomiting (PONV) alone 
comprised 20% of all ADRs investigated in the analysis. At the time this study was conducted, 
national guidelines for the prevention of post-operative vomiting (POV) in children had been  
published (Carr et al. 2009). The recommendation was to target children at high risk of POV. 
Prophylactic treatment for all children was considered “probably unnecessary, as it is 
financially costly and may results in excessive ADRs”(Carr et al. 2009). It would be interesting 
to assess, whether these guidelines were already followed in the post-operative 
management in this study. If not, a follow up study could ascertain whether an 
implementation of these guidelines has been more effective in preventing PONV. Carr et al. 
also highlight the lack of research focussing “on the children’s perspective of POV, and 




al. 2009) This is true not only for POV but also for other ADRs.  Some of the most common 
reactions, constipation, pruritus and urinary retention are likely to be experienced as 
distressing by the patient and further investigation in this area is warranted. 
2.5.5 Limitations 
The observational approach depends on documentation by the clinical team regarding signs 
and symptoms and is thus a limitation of this study. A further limitation was the exclusion of 
the PICU setting, which is likely to have led to a lower overall ADR incidence as the incidence 
of ADRs on PICU is likely to be higher than in a ward setting. Silva et al. reported 110 proven, 
probable or possible adverse events, using the Naranjo algorithm, in 84 of 239 PICU patients 
(35.1%) (Silva et al. 2013). Their case definition did however not exclude drug or 
administration errors. The decision to exclude PICU from this study was deliberate as the 
assessment of ADRs occurring in a PICU setting is more difficult and requires different 
methodologies for detection. Ideally, paediatric intensive care specialists – clinicians, 
pharmacists and nurses – should be part of the research team identifying and assessing ADRs 
in this environment.  
The methodology was geared towards detecting known, previously described ADRs. It is 
therefore possible that novel ADRs were missed in this study. It is also possible that novel 
ADRs were detected but categorised as unlikely or possible. Furthermore ADRs with delayed 
onset, occurring after discharge from hospital or only developing slowly, for example after 
recurrent exposure, would not have been regularly identified in this study. Examples for 
these types of reactions are peripheral neuropathy induced by vincristine and ototoxicity 
induced by cisplatin. In addition, despite intense surveillance, it is possible that some 
detectable ADRs occurring during the inpatient stay, were missed. Any ADRs occurring in 
patients admitted for less than 48hrs would not have been included in this study, although 
these were probably the less serious ADRs. Similarly ADRs requiring readmission to hospital 
would not have been captured, however, we have studied the latter category in a separate 
study of ADRs which required admission to hospital (Gallagher et al. 2012).  
It is unsurprising, that oncology treatment was confirmed as a significant risk factor for ADRs 
in this study, considering the significant toxicity many chemotherapeutic agents produce. 
However, immunosuppressant drugs like methotrexate or cyclophosphamide, which were 




used in rheumatology treatment. This and other “speciality treatment” was not investigated 
as separate risk factor and is a limitation to the risk factor analysis.  
Finally, differentiating symptoms due to an underlying condition from those caused by drugs 
(e.g. tachycardia in patients being treated for acute asthma) remains a challenge.  
2.6 Conclusions   
The data of this study show that 17.7% of all children who spent more than 48 hours as an 
in-patient experienced at least one ADR. This is a higher incidence than in adults, but it is 
likely that the true incidence was underestimated as “possible” and “unlikely” ADRs were 
excluded. 58% of ADRs observed in our study occurred in patients undergoing a procedure 
under GA, which increased the risk of developing an ADR by more than six times. Drugs used 
in perioperative management appear to be a major risk factor for experiencing an ADR, thus 
systematic monitoring of common and severe adverse effects of these drug groups would 
be an important step towards improving their safety. Advances in pharmacogenomics could 
improve drug safety of perioperative pain management further. ADRs may also be an 
important problem in children who are discharged home shortly after surgery. Given the 
ongoing strategies to increase the proportion of children having day case surgery (Koenig & 
Gu 2013; NHS Modernisation Agency 2004), this warrants further investigation.  
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3 Estimating the financial burden of ADRs - assessment of the 
contribution of ADRs to the duration of hospital stay in children 
3.1 Background 
The economic burden of ADRs to society is significant. The annual cost of ADR related 
admissions for the NHS has been estimated to be £466 Million (Pirmohamed et al. 2004). 
For inpatients, considering excess bed days due to ADRs alone, the financial impact for adult 
patients in the UK has been estimated to be £5000 per bed per year, which would amount 
to at least £2 Million per year for a 400-bed hospital (Davies et al. 2009). Similar estimates 
have been given in studies in France and the US (Bates et al. 1997; Moore et al. 1998) 
Economic impact may consider direct and indirect costs. Direct costs arise for example from 
hospital admissions due to ADRs, extension of hospital stay, additional investigations, 
additional treatment (including invasive and non-invasive procedures), involvement of 
additional clinical expertise or transfer to higher level of care and indirect costs from 
disability, loss of earnings or absence from studies, litigation costs and repeated hospital 
visits. Many of these costs are difficult to quantify, particularly in large, population based 
studies. Estimates of the financial impact of ADRs have therefore mainly been based on 
pragmatic approaches and data that are easily available (Gautier et al. 2003). Cost 
calculations for ADRs causing hospital admissions are relatively straight forward, as the 
entire duration of the hospital stay can be used for cost calculations. On the other hand, for 
ADRs occurring after admission to hospital, only costs that are directly attributable to the 
ADR can be included in any estimates. The most informative but also most resource intensive 
approach of making these estimates is a detailed case review with patient specific data 
collection (‘microcosting’) (Jackson 2000). A more readily available proxy measure is 
calculating the excess bed days due to ADRs, often using a matched case-control study 
design. However, without adjustment for confounding variables such as comorbidities, 
number of drugs etc., this approach is likely to become inaccurate (Rodríguez-Monguió, 
Otero & Rovira 2003). Alternatively, excess bed days can be assessed on a case-by-case basis, 
relying on professional judgement. Excess bed days are then translated into cost by using 
average bed-day cost estimates (‘per diem’ cost). Diagnosis related approaches have also 
been used, for example using international classification of diseases (ICD) or diagnosis-




this approach can also become problematic as the overall cost difference for the same 
diagnosis may be significant. For example, a patient who develops drug-induced acute renal 
failure may recover quickly and fully within a few days, whereas a different patient 
developing renal failure after being exposed to the same drugs may require weeks to recover 
fully or may even develop chronic renal failure.  
3.1.1 Overview of literature investigating the financial impact of ADRs in 
hospitalised patients 
Rodriguez-Monguio et al. reviewed studies investigating the financial impact of ADEs and 
found that most studies have been carried out in acute care settings in the US and are mainly 
considering direct costs for the hospital (Rodríguez-Monguió, Otero & Rovira 2003). They 
also highlighted that due to methodological differences studies may not allow comparison. 
Concerning the financial impact of ADEs in hospitalised patients, they identified 7 studies, all 
of which were based in US hospitals. Although some of these studies included paediatric 
patients, paediatric specific data on cost implications were not available from the original 
publications. In addition, data were given for ADEs and not ADRs (1.3.2 and 1.3.3). More 
recently Davies et al. have provided an estimate of attributable duration of stay from ADRs 
in adult inpatients (above) (Davies et al. 2009). In contrast to most of the US based studies 
employing a matched case control study design, they assessed ADRs on a case-by-case basis, 
taking into account clinical and social information such as underlying disease, additional 
medication, awaiting placement in nursing home etc. Clinical judgment was used to make 
the final decision. 
There is a lack of paediatric studies assessing the financial impact of ADRs. Although several 
paediatric inpatient ADR studies (dos Santos & Coelho 2006; González-Martin, Caroca & 
Paris 1998; Martínez-Mir et al. 1999; Weiss et al. 2002) and one including both adult and 
paediatric patients (Gholami & Shalviri 1999) have identified a longer duration of stay as a 
risk factor for ADRs, few have attempted to describe whether the ADRs detected are actually 
contributing to the increased duration of stay. Weiss et al. reported that 5 of the 68 ADRs 
(7.8%) they identified in 214 inpatients were responsible for the prolongation of the hospital 
stay (Weiss et al. 2002). No details were provided on how they assessed the cases and 
reached this conclusion. In a prospective study of 1339 paediatric admissions, Haffner et al. 
found that children with ADR stayed longer in hospital (median stay 6 days vs. 4 days without 




attributable to ADRs were therefore uncertain (Haffner et al. 2005). Martinez-Mir et al. 
found that children with ADR stayed longer in hospital than those without (average 4.66 days 
longer; total number of admission n= 40) (Martínez-Mir et al. 1999). However, children with 
ADR in this study had also been exposed to a larger number of medications, which is a known 
risk factor for ADRs 2.5.3 and may also be an indicator for severity and/or complexity of the 
underlying medical condition(s).  
3.1.2 Assessment of financial impact of ADRs in this study 
Given the considerable financial burden of inpatient ADRs in adults and the paucity of 
equivalent data in the paediatric population, a cost estimation to assess the economic 
burden of ADRs in hospitalised children was included in this study. Employing a similar 
approach as Davies et al., a duration of stay assessment was included in each ADR 
assessment as part of the study methodology.  The researcher completing the detailed ADR 
case report in the study database (2.3.7) answered the following questions: ‘Did the ADR 
prolong the hospital stay (yes/no/possible); if yes, for how long (in days)?’ Preliminary 
analysis of the results indicated that only 1.24% (18/1446) of ADR cases led to a prolonged 
hospital stay. Given the significant difference to Weiss et al. (3.1.1) and to adult data, a study 
using a similar study design and assessment methods, it was possible that this had been an 
underestimate and that the methodology used had not captured all ADR cases that 
prolonged the hospital stay.  
3.1.3 Objective and Aims  
The aim of this additional study was therefore re-assessing excess bed days attributable to 
ADRs in a paediatric inpatient population by  
• developing an alternative methodology to assess the contribution of ADRs towards 
prolonged hospital stay. 
• assessing the feasibility of this methodology in a pilot study and identifying any 
modifications needed. 





3.2 Methodology  
This study was planned and conducted by ST, the author of this thesis. ST also developed the 
methodology, contributed to data collection during all stages (see also 3.2.4) and analysed 
the results. 
3.2.1 Stage 1a – Evaluating methods of assessment of duration of stay 
3.2.1.1 Matched case control study  
One advantage of using a matched case control study design is, that it is not dependant on 
the knowledge and experience of the assessor thus avoiding potential bias introduced by 
using clinical judgement. However, when comparing duration of stay in patients with and 
without ADR, the result is likely going to overestimate the contribution of ADRs unless the 
chosen matching criteria include a wide variety of confounding factors (Rodríguez-Monguió, 
Otero & Rovira 2003). During the design stage of the study reported in the chapter the risk 
factor analysis (2.3.11) had not yet been completed and it was difficult to know which criteria 
should be used to match cases and controls. Even if the outcome of the risk factor analysis 
had been known, vital clinical parameters were not available in a format that would easily 
allow them to be used as part of the matching process. Data such as underlying diagnosis, 
comorbidities, and type of procedure (for patients who had undergone a GA) had been 
collected in ‘free text’ format. It would have been very time consuming to standardise this 
information e.g. by using MedDRA terminology or International Classification of Diseases 
(ICD) coding.  For many cases, it would have been difficult to find an appropriate matched 
control e.g. a post-operative cardiac patient with one or several ADRs may have an 
unexpectedly prolonged stay due to post-operative complications and it is hard to imagine 
that a patient with similar age, sex, and underlying diagnosis would have undergone a near 
similar procedure and developed the same complications. In addition, there was a significant 
number of patients with multiple ADRs in this study, which would have complicated the 
matching process further. In summary, a matched case control study was not deemed 
suitable for the given study design and study population. 
3.2.1.2 Expected discharge versus actual discharge date  
Upon admission to hospital, each patient receives a nursing assessment which is entered 




The feasibility of using these data to estimate excess bed days in all or perhaps at least a 
specific group of patients, e.g. patients admitted for well defined, elective procedures, was 
therefore explored through informal interviews with senior nursing staff with expertise in 
the care of orthopaedic, ENT, cardio-thoracic and general medical patients. For all patient 
groups, setting of the expected discharge date was based on the discretion and therefore 
individual experience of the nurse entering the patient data into the hospital database. 
There were no guidelines or protocols for this process and the approach was therefore also 
not deemed suitable for assessment of excess bed days.  
3.2.1.3 Case-by-case assessment 
Clearly, this approach had already been used for this study and potentially underestimated 
the burden. At the same time, it had been successfully used by Davies et al. in a similar sized 
single centre, adult, UK based study. Their assessment of whether an ADR directly led to an 
increase in duration of stay, was based on the clinical features of ADR and the underlying 
medical condition(s). The process included discussion with the medical team and the ward 
pharmacist and a review of relevant medical notes. Our methodology did not explicitly state 
how the duration of stay assessment should be made and there were no guidelines or 
requirements to discuss cases with the medical team or ward pharmacists. Although the 
medical notes had been reviewed for all ADR cases (2.3.7; Table 2.2), this might not have 
provided enough information for the researcher compiling the ADR case report to make the 
duration of stay assessment. Whereas in adult medicine patients are generally highlighted 
as ‘ready for discharge’ as soon as they judged to be medically fit for discharge, paediatric 
patients are generally considered ready for discharge when everyone involved in the child’s 
care is happy for his/her discharge. For example, it is not unusual for a child to stay an 
additional night for parental reassurance. It was therefore possible that cases where the ADR 
did prolong the stay had been misclassified.  
Due to the large number of different medical teams involved it would not have been feasible 
for this study to revisit each ADR and discuss each case with the clinical team involved. 
Bearing in mind that most ADRs are likely not to prolong duration of stay, the possibility of 
reducing the number of ADR cases that would have to be re-assessed by reliably excluding 




3.2.2 Stage 1b – Defining criteria for exclusion of ADRs that did not prolong 
duration of stay 
3.2.2.1 Exclusion by end date of ADR 
A pragmatic ‘cut-off’ of 2 days or more was chosen, as it is unlikely that an ADR ending 2 
days before discharge or more, would prolong the hospital stay. For ADRs ending less than 
2 days before discharge, there is a possibility that this might have influenced the hospital 
stay, e.g. for a child with vomiting, the clinical team and/or the parents might have wanted 
to have an additional period of observation to be certain that the child was tolerating diet 
and fluids prior to discharge. 
3.2.2.2 Exclusion by reaction type 
All reaction types were considered and only 3 reaction types were identified that very likely 
would not have prolonged the hospital stay: 
• Topical candida infections 
• Pruritus due to opioids  
• Agitation/Tremor/Tachycardia due to salbutamol or aminophylline, drugs used in 
the treatment of acute exacerbations of asthma 
Topical candida infections, as associated with use of systemic antibiotics, can be treated in 
the community and would not delay discharge. Duration of opioid treatment is dependent 
on other factors.  Once opioids are discontinued the pruritus resolves and will therefore not 
delay patient discharge. Similarly, Asthma treatment is dependent on clinical factors.  Once 
the patient improves clinically, the treatment can be reduced and the symptoms normalise 
or resolve and will therefore not delay patient discharge. 
For all other reaction types, it could not be ruled out that the reaction did not delay 




3.2.3 Stage 2 – Pilot of proposed methodology 
The most time limiting factor for re-assessment was going to be access to the medical notes.  
These had to be requested through the hospital’s medical records department, only a limited 
number of medical notes could be requested per day and clinical requests would of course 
always take priority. One aim of the pilot study was therefore to assess which data sources 
would be required to re-assess all ADR cases (Table 2.1) by estimating how many cases could 
be assessed by revisiting the database entry and/or electronically available data and for how 
many case reports medical notes would have to be requested. 
First, the case summary stored the study database would be re-visited, then, if required, the 
hospital database and finally, if still more information was required to reach a decision, the 
medical notes would be reviewed. At each step the possible outcome for extended hospital 
stay was Yes/No/Unsure. Each assessor was asked to record where they found the relevant 
information (study database/hospital database/medical notes). A list of ADRs by ADR 
identification number (ADRID) was compiled. An ADRID was assigned automatically, by the 
study database, each time a new ADR case report is opened but ADRs had not necessarily 
been assessed in chronological order. At the time of this pilot study not all ADR assessments 
had been assigned a final causality outcome (2.3.7.1), therefore only those ADRs who had 
received their final causality outcome were included. Furthermore, the analysis plan had not 
yet been finalised and therefore ADRs with the outcome possible, probable and definite 
where included. After exclusion of those ADRs, deemed unlikely to have prolonged the 
hospital as per criteria above (3.2.2), every 3rd ADR was considered for assessment during 
the pilot study. ADRs that had already been identified as having prolonged the hospital stay 
using the original methodology, were not included. The following instructions for 
assessment were also given to the research team:  
The aim of this assessment is to either confidently rule out that the ADR has caused prolonged 
the hospital stay or to highlight that the ADR has prolonged the stay and by how many days. 
There will be a considerable number of cases where we are unsure. For each level of 
assessment (i.e. 1. study database 2. hospital database 3. medical notes) please record one 
of the following 3 outcomes Yes/No/Unsure 
• Yes: If it is not possible to determine by how many days the stay was prolonged please 
make a note of 1) whether it would be possible to give a range e.g. 1-2 days 2) whether 




• No: We can only confidently answer NO if there is indication that the patient needed to 
stay for other reasons. Therefore, please record the rationale behind making this 
decision. We need to be very careful in making this decision based on what information 
is available. It might well be that although a patient with constipation opened his/her 
bowels the day before discharge he/she was not discharged because of indirect reasons 
related to that (transport, time of day, take home medication, unavailability of medical 
staff to make decision etc.). 
• Unsure: Record this outcome if you can’t confidently say yes or no based on the 
information available. Continue with next level of assessment. 
3.2.4 Stage 3 – Re-assessment of contribution of ADRs to duration of stay 
After assessing feasibility and time frame of the proposed methodology during the pilot 
study, a new section was added to the study database, allowing the team to record the 
outcome of the re-assessment(s). Only ADRs that did not meet exclusion criteria 3.2.2 were 
assessed.  In addition, for ADRs that had been originally identified as prolonging stay the 
time scale were also re-assessed, as the original outcome had been recorded in a different 
section of the database. A rationale had to be recorded for each outcome decision, e.g. LOS 
prolonged? No - stayed to complete chemotherapy.  Duration of stay was recorded in days. 
If the discharge was delayed but the patient was still discharged within the same 24hr period 
this was recorded as 0.5 days, but not included in the total cost calculation as bed day costs 
were calculated/24hr period. 
To add validity, each case was assessed independently by either two research pharmacists, 
or one research pharmacist and a research nurse. If the two assessors agreed on the 
outcome this was considered the final outcome. In the case of discrepancy, the ADR was 
then reviewed again by a paediatrician (ST). Finally, any ADR cases where the outcome 
remained uncertain, were then referred for review by a panel of two senior investigators. 
All other aspects of the assessment were conducted as described for the pilot study. In line 
with the overall analysis plan, all ADRs that occurred prior to transfer to higher level of care 
were also assessed by a paediatrician (ST) and, if required, by a panel of two senior 
investigators (2.3.7.3). In line with the final study methodology, only the results for probable 
and definite ADRs were reported. Bed day costs were calculated using cost information 





3.3 Results  
3.3.1 Results of Stage 2 - Pilot study  
252 ADRs with the final causality outcome possible, probable and definite were identified at 
the beginning of the pilot study (Figure 3.1). 205 ADRs were considered not to have 
prolonged the stay due to reaction type and 647 due to end date of ADR.  Of the remaining 
420, 15 had already been highlighted as having prolonged the hospital stay and were 
disregarded for purposes of the pilot study. Of the final 405 ADRs, every 3rd was re-assed 
(n=135). Results are summarised in  
Table 3.1. 111/135 ADR cases (82.2%) could be assessed using electronic data sources (study 
and hospital database) alone. For 11 of the remaining 20 ADR cases (55%), a decision was 
reached after assessment of the medical notes. 6 cases were referred for next level review 
(paediatrician) and for 3 cases the medical notes were recorded as missing. In total 126 ADR 
were completed, of these, 6 ADRs (4.8%) were considered having prolonged the hospital 
stay by a total of 8.5 days (range less than 1 to 3 days). 





Table 3.1 Assessment of excess bed days due to ADRs - Results of pilot study (n=135) 
Source  Total N of 
ADRs 
Did ADR prolong stay? N of ADRs for each 
outcome 


















*For 3 cases the medical notes were missing 
3.3.2 Results of Stage 3 – Re-assessment of contribution of ADRs to duration of 
stay 
Of 1446 ADRs included in the study analysis (2.4.2), 284 were considered not to have 
prolonged the stay due reaction type and 630 due to end date of ADR (Figure 3.2). The 
remaining 532 ADRs were re-assessed.  
27/1446 ADRs (1.9%) were identified as having prolonged the hospital stay by a total of 61 
days (average 1.9 days; range 0.5 -12 days). Two patients experienced two ADRs that were 
both evaluated as having prolonged the stay by one day: A patient with dizziness post GA 
and PONV and an oncology patient with pain and oedema. As these ADRs occurred during 
the same admission, they were only counted once towards the total number of excess bed 
days. In 3 cases the excess bed days were censored as the patients died before discharge. 
Details of the reaction types and medicines involved are summarised in Table 3.2. The most 
common reaction type causing a prolonged stay was PONV (8/27; 29.6%) with up to 3 excess 
days per patient.  The most common drug group associated with ADRs prolonging the stay 
were drugs used in GA (10/27 ADRs; 37.0%). Nearly one third of reactions occurred in 
oncology patients (8/27 ADRs; 29.6%) and accounted for 20/61 days (32.8%). The total cost 





Figure 3.2 Flow chart outlining the number of ADR cases re-assessed in a structured, case 






Table 3.2 ADRs that prolonged the hospital stay by ADR type, drugs implicated and number 
of additional bed days. ADR types listed in order of frequency 
ADR type     
(N of same type if >1) 
 
Drugs implicated  
(implicated in N of ADRs if > 1) 
Total N of excess 
days caused by 
this ADR type 
(range; median)*  
PONV (8) Sevoflurane (7), nitrous oxide (7), morphine (5), 
propofol (4), codeine (4) , fentanyl (2), 
remifentanil (2), diclofenac, isoflurane, ketamine 
 14 ** (0.5 to 3; 
median 1)  
Stomatitis (3) Alemtuzumab (2), cyclophosphamide (2), 
melphalan, carboplatin, etoposide 
6 (2 ADRs censored) 
Vomiting (2) Busulphan, melphalan, vincristine, etoposide, 
doxorubicin, ifosfamide 
4 (1 + 3) 
Constipation (2)  Fentanyl and codeine (2) 1.5 (1 + 0.5) 
Cushing's syndrome Methylprednisolone, prednisolone, 
hydrocortisone 
10 
Delayed recovery from GA  Midazolam, propofol 1 
Diabetes mellitus  Dexamethasone 2 
Diarrhoea Daunorubicin, vincristine, rasburicase, 7 
Dizziness (post GA) Morphine , codeine, sevoflurane, nitrous oxide, 
propofol 
1** 
Sedation withdrawal Fentanyl, chloral hydrate 1 
Hyponatraemia Furosemide, spironolactone 2 
Oedema Aldesleukin, Anti-G2 chimeric antibody 1** 
Pain Anti-G2 chimeric antibody 1** 
Adrenocortical insufficiency Prednisolone, hydrocortisone 1 
Cardiac failure Bisoprolol 12 
Clostridium difficile colitis Meropenem, gentamicin Censored  
* If the discharge was delayed, but the patient was still discharged within the same 24hr period this was recorded 
as 0.5 days. Patients who died before discharge were censored. ** Two patients experienced two ADRs which 
were both considered to have prolonged the stay independently by one day each. These ADRs were only counted 









Ward Cost by ward type in £ 
bed/day total 
stay 
Cushing's syndrome 10 Medical 1 354 3540 
Clostridium difficile colitis Censored* Oncology and PICU  Censored* 
Cardiac failure 12 HDU 837 10,044 
Constipation 1 Cardiology 387 387 
Delayed recovery from GA 1 Cardiology 387 387 
Diabetes mellitus 2 OUA 766 1,532 
Constipation 0.5 Cardiology 387  N/A 
Diarrhoea 7 OUA 766 5,362 
Sedation withdrawal syndrome 1 Cardiology 387 387 
Hyponatraemia 2 Cardiology 387 774 
Oedema and Pain  1** Oncology 766 766 
Dizziness and PONV 1** Surgical 3 299 299 
PONV 0.5 Surgical 1 303 N/A 
PONV 1 Surgical 2 368 368 
PONV 1 Surgical 2 368 368 
PONV 0.5 Neurosurgery 459 N/A 
PONV 3 Surgical 3 299 897 
PONV 1 Surgical 4 316 316 
PONV 2 Surgical 2 368 736 
Adrenocortical insufficiency 1 Surgical 1 303 303 
Stomatitis Censored* Oncology and PICU  Censored* 
Stomatitis Censored*  Oncology and PICU  Censored* 
Stomatitis 6 Oncology 766 4,596 
Vomiting 1 Oncology 766 766 
Vomiting 3 Oncology 766 2,298 
 Sum of excess bed day costs in £  34,126 
* Cost for was not calculated for patients whose discharge was delayed less than one day and patients who were 
censored. ** These patients experienced two ADRs which both prolonged the same admission by one day and 
were therefore only counted once towards the total cost of extended duration of stay.  
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3.4 Discussion 
Our data suggest that only a small number of ADRs (27/1446; 1.9%) in hospitalised children 
prolong the overall hospital stay. Given that less than 1% of ADRs were considered severe (2.4.2), 
these numbers are perhaps not surprising. Weiss et al. reported 7.8% of ADRs in their study had 
prolonged duration of stay (Weiss et al. 2002). However, their population was much smaller 
(n=214) and the study was conducted in a very specific setting, a 10-bed isolation ward.  They 
identified 68 ADRs in 46 patients and antibiotics were implicated in 50% of ADRs vs 10.6% in this 
study (Table 2.10).  
The resulting financial impact of prolonged duration of stay in our study amounts to approximately 
£35,000 per year for a 300-bed hospital (of these, 22 PICU beds). Comparable adult studies have 
estimated costs for prolonged stay caused by ADRs to be more than 40 times higher (£2 million 
for a 400-bed hospital) (Davies et al. 2009). This discrepancy may be partly explained by the 
different spectrum of ADRs and medicines implicated. To give just two examples, the most 
commonly implicated group of medicines in Davies’ study were diuretics (20.6%), whereas these 
featured low in this study (1.36%). The ADRs associated with diuretics included renal failure, which 
is much rarer in children and was indeed not observed in this study. Penicillin, cefalosporins, and 
macrolides together, were implicated in 24.9% of ADRs in Davies’ study but all antibiotic groups 
together were implicated in only 10.6% in this study. ADRs associated with antibiotics included 
Clostridium difficile infection (CDI) which is frequently associated with prolonged hospital stay and 
occurs more commonly in adults than in children: Studies from the US report 8.2 vs 3.1 cases of 
CDI per 1000 discharges in adult and paediatric inpatients respectively, and higher mortality rates 
in adults (7.2%) compared to children (1.7%)(Deshpande et al. 2013; Reveles et al. 2014). In this 
study only 7 patients developed clostridium difficile colitis which in one patient lead to an 
extended duration of stay. 
Studies assessing the financial burden of ADRs in the paediatric population remain scarce. In a 
recent study of 697 PICU admission, Du et al reported that the duration of stay for patients with 
ADRs was 3.8 times longer and the total ICU cost was 3.5 time higher (Du et al. 2013). They had 
observed an ADR incidence of 13.1% and used a matched case-control approach to assess excess 
bed days, adjusting for clinical and demographic factors. In contrast to this study, 72.2% of 
observed ADRs were electrolyte imbalances and 69.1% of ADRs were associated with diuretics.  
Using a national US database and code identified ADRs, Tundia et al. estimated the mean excess 
bed days for AE (excluding accidental poisoning, but including medication errors) to be 1.5 days 
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and the mean excess cost to be $3842. However, the significant differences with regards to study 
design (retrospective, case-match control, age 0-20) and methods (code identification of ADRs 
and diagnoses, ADR definition included medication errors, direct cost estimation using charge 
data) make a direct comparison of the financial impact with this study again problematic. For 
example, ADE (that comprises AEs but also cases of accidental poisoning) were identified in only 
0.9% of all patients, which suggests that not all ADRs that occurred in hospital were coded. It is 
likely, that ADRs that were considered minor and did not prolong the stay and hence would not 
count towards the overall charge of the hospital stay, are underrepresented when considering 
coding data only. Assuming a similar ADR incidence rate as in our study (17.7%) and excluding 
medication errors, accidental poisoning and patients older than 16 (32.5% of all AEs identified in 
Tunida et al.’s study occurred in 16-20-year-old patients), the percentage of ADRs leading to an 
extended duration of stay would perhaps be closer to 2-3%, making it comparable to our findings. 
3.4.1 Limitations 
With the methodology used, ADRs with an indirect effect on the duration of stay would not have 
been captured. For example, a child who developed chemotherapy related diarrhoea and 
vomiting and required total parental nutrition (TPN), could have developed TPN related hepatitis 
which might have prolonged the hospital stay. As reactions to TPN were not included in the study 
methodology this would have been missed. In addition, if the first ADR, diarrhoea and vomiting, 
ended more than 2 days before discharge, this ADR would not have been assessed for duration of 
stay. An admission based assessment could capture these indirect effects of ADRs but would not 
have been a feasible approach given the large number of ADRs in this study.  
Furthermore, intermittently occurring ADRs, that prolonged the hospital stay could have also been 
missed as in accordance with the study methodology this study, only the first ADR was counted 
(2.3.11). For example, Children who received pulsed high-dose intravenous methylprednisolone, 
might have developed hypertension that initially did not require treatment, but worsened 
throughout the course and required treatment towards the end, which then may have prolonged 
the hospital stay. If the episode of hypertension ended more than 2 days before discharge, this 
would not have been investigated and therefore would have been missed.  
In some cases, it might be difficult to quantify the contribution of the ADR to the overall duration 
of stay. For example, a child with PONV might have stayed an additional night for parental 
reassurance and it would have been difficult to quantify the contribution of the ADR to parental 
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anxiety. It is likely that such ADRs would have not been highlighted as having contributed to the 
duration of stay. 
Some ADRs with significant cost implications would not necessarily lead to an extended duration 
of stay and would therefore not have been captured at all. For example, the lifetime cost of a 
single case of severe hearing loss in an infant has been estimated to be more than $ 1 million 
(Shield 2006). 
Toxicity from treatment of acute asthma with Salbutamol and Aminophylline, include agitation, 
tremor, tachycardia and vomiting. However, tachycardia and agitation, may also be caused by 
hypoxia due to acute asthma and it can be challenging to distinguish between these two. On 
reflection, it is quite possible that an ADR in this patient group was mistaken for poor response to 
treatment and treatment was prolonged unnecessarily. This is turn could have led to a longer stay 
than clinically necessary and thus could have contributed to the total number excess bed days due 
to ADRs. These reactions should have therefore been included into the re-assessment. 
In line with the analysis of the main study, only ADRs with the causality outcome probable or 
definite were considered in this study. ADRs with the outcome possible might well have 
contributed to excess bed days, but were not included in this analysis. 
The author of this thesis has no experience in the field of health economics and involving a health 
economist would have added validity to this study. In addition, a sensitivity analysis, for example 
re-assessment of a random sample of excluded ADR cases (Figure 3.2) would have strengthened 
the analysis.  
3.4.2 Conclusion 
Only a small number of ADRs in hospitalised children lead to prolonged hospital stay and the 
resulting costs from excess bed days are relatively low compared to adult studies. However, 
indirect costs, for example the financial burden for the family arising from an extended hospital 
stay were not considered. This burden might be considerable as it could involve one parent losing 
a job or having to give up a job, to care for the child. 
To estimate the economic burden of paediatric ADRs, more, carefully designed studies are 
required, including community settings and considering costs arising after discharge. However, to 
fully investigate and understand the burden of ADRs to the child, patient/carer and the health 
system, studies need to look beyond these aspects. Assessing patient reported outcome measures 
(PROMs) with a specific focus on ADRs would perhaps be a good starting point.  
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4 Thiopurine-S-Methyltransferase (TPMT) and Cathecol-O-
Methyltransferase (COMT) genetic variants in paediatric cancer 
patients with cisplatin-induced ototoxicity  
4.1 Introduction  
As highlighted in the previous chapter, some ADRs may have significant socio-economic 
implications. The lifetime cost of a single case of severe hearing loss in an infant has been 
estimated to be more than $ 1 million (Shield 2006). In addition, permanent hearing loss is a 
devastating prospect for any child as it affects crucial areas of development, such as speech and 
language, communication and social skills, and overall academic skills. For example, children with 
minimal degrees of sensorineural hearing loss (SNHL) may experience significant speech 
recognition difficulties in the presence of background noise, for example in a normal classroom 
environment (Crandell 1993). Even minimal SNHL can thus affect both academic ability (37% 
failing at least one school grade) and overall level of function (behaviour, energy, stress, social 
support, and self-esteem) (Bess, Dodd-Murphy & Parker 1998).  
A drug well known to cause permanent hearing loss in a large proportion of children exposed to 
it is cisplatin, a chemotherapeutic agent used to treat solid malignancies in childhood, both within 
the central nervous system (CNS) (e.g. medulloblastoma) and in the rest of the body (e.g. 
osteosarcoma, neuroblastoma, hepatoblastoma). Cisplatin is highly effective and hearing loss 
might thus seem “a small price to pay” for children undergoing lifesaving treatment. However, 
due to life changing effect of permanent hearing loss, children undergoing cisplatin treatment are 
proactively and tightly monitored for ototoxicity. Once significant hearing loss is confirmed, 
treatment will often be changed to alternative treatment with carboplatin. However, ototoxicity 
is irreversible and it would be desirable to be able to identify children at high(er) risk of developing 
cisplatin induced hearing loss before treatment is commenced, thus allowing clinicians to discuss 
treatment options with the parents and or the child.   
4.1.1 Cisplatin induced hearing loss 
Cisplatin induced hearing loss occurs  typically as bilateral, irreversible, high-frequency (HF; > 4000 
Hz) sensorineural hearing loss (McHaney et al. 1983). With increasing severity, the hearing loss 
can also affect lower frequencies.  
  68 
HF hearing loss impairs the recognition of several consonants, which are critical for speech 
comprehension, in particular s, f, th, sh, h, k and t (Stelmachowicz et al. 2004).  
4.1.2 Incidence of cisplatin-induced hearing loss 
Reported incidence rates for cisplatin-induced hearing loss in children range between 42 and 88% 
(Brock et al. 1991; Brock et al. 2012; Coradini et al. 2007; Li, Womer & Silber 2004; McHaney et al. 
1983; Paulino et al. 2010; Ross et al. 2009; Skinner et al. 1990).  The wide difference is 
unsurprising, considering that study populations have often been small (median study size 36.5 
patients; range 22-162), and mostly heterogeneous with regard to diagnoses (single tumour type 
- varying types), median age (2 years 2 months – 13 years), age range (youngest included patient 
1 months – 10.4 years; oldest included patient 8 years - 23 years), dosages (mean cumulative 
cisplatin dose 397-540 mg/m2), treatment schedules, record of exposure to other ototoxic agents 
(4.1.3) and concomitant radiation (none - 100%). In addition, there is no consensus about how to 
define and grade cisplatin related hearing loss, which leads to significant variability in the 
assessment of ototoxicity. An overview of studies investigating cisplatin-induced hearing loss is 
given in Table 4.1. 
4.1.3 Risk factors 
Established risk factors for the development of hearing loss in children receiving cisplatin therapy 
include increased cumulative dose of cisplatin (Brock et al. 1991; Coradini et al. 2007; Li, Womer 
& Silber 2004; McHaney et al. 1983; Schell et al. 1989), younger age (Brock et al. 1991; Coradini 
et al. 2007; Li, Womer & Silber 2004; McHaney et al. 1983; Schell et al. 1989), cranial irradiation 
(Hua et al. 2008; Paulino et al. 2010; Schell et al. 1989) and carboplatin in myeloablative doses 
(Parsons et al. 1998; Punnett et al. 2004). The role of exposure to other potentially ototoxic 
medication is less clear, largely owing to the significant variability of the medications investigated 
(treatment protocols differ between cancer types and risk groups) (Table 4.2). One early study did 
not investigate this aspect (McHaney et al. 1983) while two more recent studies did not comment 
on exposure to other medications (Li, Womer & Silber 2004; Paulino et al. 2010). Knight et al. 
concluded that concurrent administration of long-term intravenous gentamicin had likely 
contributed to increased hearing loss in two patients (Knight, Kraemer & Neuwelt 2005). In 
contrast, three studies did not find an increased risk of hearing loss with various concomitant 
potentially ototoxic medications (Brock et al. 1991; Coradini et al. 2007; Skinner et al. 1990)(Table 
4.2). 
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4.1.5 Pharmacogenetics of cisplatin-induced hearing loss 
There appears to be significant inter-individual variability in predisposition to cisplatin-induced 
hearing loss (Brock et al. 1991; Skinner et al. 1990). The observed differences in toxicity are greater 
than the variability in pharmacokinetics, despite equivalent doses. Irreversible hearing loss can 
occur after a single dose of cisplatin whereas some children do not develop hearing loss even after 
multiple and high doses of cisplatin (Brock et al. 1991). It is therefore likely that genetic factors 
influence cisplatin-induced hearing loss (Skinner et al. 1990). Several studies have identified 
potential predisposing genetic variants, but the evidence for most of these remains controversial. 
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Table 4.1 Studies investigating cisplatin-induced hearing loss. Comparison of size, mean age, age range, diagnoses, dosage, exposure to cranial irradiation, 
percentage and definition of hearing loss 
Author , year Size 
(n) 
Age                                              
mean (range) 











(MCHANEY ET AL. 1983) 
24 median 7 years                   
(3.5 years, 17.5 years) 
neuroblastoma (66.5%) or other 
solid tumours 




(SKINNER ET AL. 1990) 
22 13 years                                     
(7 years, 19 years) 
osteo 50%,  PNET 22.7%, 
rhabdo 13.6%, other (non CNS) 
13.6%  
542 (312, 1072) 9.0% Brock 73.0% 
Brock, 1991    
(Brock et al. 1991) 
29 median 2 years 2 months      
(1 month, 13.5 years) 
neuroblastoma 62.0%, GCT 
27.3%, other (non CNS) 10.3% 
540 (120, 1680) none Brock 47.5% 
Li, 2004 (LI, WOMER & 
SILBER 2004) 
153 no mean/median                     
(6 months, 18 years) 
hepatoblastoma, GCT, 
neuroblastoma, osteo 
397  (120, 1213) none Brock 52.6% 
Knight, 2005 (KNIGHT, 
KRAEMER & NEUWELT 
2005) 
67 9.65 years                               
(8 months, 23 years) 
varying, including CNS mean 493c)                                         34.3% Brock/ASHAf)/CTCAE 41.8% 
Coradini 2007 
(CORADINI ET AL. 2007) 
23 12.3 years                             
(10.4 years,  16.1 years) 
osteo (61%), GCT, hepatic 
tumor, 
406 (317, 575) none  >20db HL 4 , 8 kHz 52.0% 
Ross 2009 (ROSS ET AL. 
2009) 
162 cases: 6 years  
controls: 9 years                     
(0, 19 years) 
varying, including CNS 400 (100, 720) 18.5% CTCAE 65.4% 
Paulino 2010 
(PAULINO ET AL. 2010) 
44 median 9 years                      
(33 months, 8 years) 
medulloblastoma 300d)  and  450e)  
(75, 562.5) 
100.0% POGg) 75.0% 
a) GCT = germ cell tumor; PNET = primitiv neuroectodermal tumour; osteo = osteosarcoma, rhabdo = rhabdomyosarcoma;   
b) for patients graded according to any hearing scale hearing loss was defined as > grade 0; c) median and range not given d) patients with grade 0-3 ototoxicity; e) patients with grade 4 
ototoxicity f) ASHA = American Speech-Language-Hearing Association g) POG=Paediatric oncology group  
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Table 4.2  Studies investigating cisplatin-induced hearing loss. Comparison of size and concomitant exposure to potentially ototoxic medication  
Author , year Size (n) Exposure to potentially ototoxic medication 
Author , year 24 none - patients with exposure were excluded 
McHaney, 1983 (MCHANEY ET AL. 
1983) 
22 gentamicin, vancomycin, netilmicin, amphotericin B, bleomycin 
Skinner, 1990 (SKINNER ET AL. 1990) 29 gentamicin, furosemide, bleomycin 
Brock, 1991 (BROCK ET AL. 1991) 153 no data 
Li, 2004 (LI, WOMER & SILBER 2004) 67 gentamicin, carboplatin 
Knight, 2005 (KNIGHT, KRAEMER & 
NEUWELT 2005) 
23 aminoglycosides, amitriptyline, ampicillin, amphotericin B, atropine, carboplatin, cephalexin, clarithromycin, furosemide, 
ibuprofen, mannitol, metronidazole, naproxen, and vinblastine. 
Coradini 2007 (CORADINI ET AL. 2007) 162 gentamicin, vancomycin, tobramycin, vincristine 
Ross 2009 (ROSS ET AL. 2009) 44 none - use of proposed ototprotective agent amifostine 
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4.1.5.1 Megalin 
In a cohort of 50 children on cisplatin treatment (25 with hearing loss, 25 controls), the A-
allele of the Megalin SNP rs2075252 was observed more frequently in the group with hearing 
impairment (p<0.016, OR 3.45; 95% CI 1.11-11.2) (Riedemann et al. 2008). In a Canadian 
study of 162 paediatric patients, an association between the A-Allele and cisplatin related 
hearing loss could not be demonstrated (Ross et al. 2009).  
4.1.5.2 Glutathion-S-transferases (GSTs)  
Peters et al. found that a GSTM3 allele was associated with protection against hearing loss 
in 39 children and young adults treated with cisplatin (p=0.02, OR and 95% CI not given). The 
group did not find an association between cisplatin-induced hearing loss and GSTT1, GSTM1 
or GSTP1 polymorphisms. In an adult population of 173 testicular cancer survivors, 
Oldenburg et al. found that a GSTP1 variant protected against cisplatin-induced hearing loss 
(p < 0.001, OR 4.21; 95% CI 1.99-8.88) and presence of a GTSM1 variant carried an increased 
risk of hearing loss (p=0.022, OR 2.36; 95% CI 1.13-4.93) (Oldenburg et al. 2007b). The same 
group described the association of the GTSM1 variant with hearing loss again in an extended 
population of 238 adult testicular cancer survivors (p=0.025, OR 1.81; 95% CI 1.08-3.3). 
Furthermore, they found a GSTP1 variant to be protective against tinnitus (p=0.008, OR 0.33; 
95% CI 0.44 -0.74) but not hearing loss (p= 0.553; OR=0.81; 95% CI not given) (Oldenburg et 
al. 2007a). Barahmani et al. did not find an association with GSTT1, GSTM1 or GTSTM1T1 
combined (Barahmani et al. 2009) and Ross et al. did not find an association with GSTP1 or 
GSTM1 and hearing loss (Ross et al. 2009).  
4.1.5.3 TPMT and COMT 
In a Canadian cohort study of 162 paediatric patients receiving cisplatin therapy, of which 
106 (65%) had hearing loss, Ross et al. identified an association with genetic variants in TPMT 
and COMT (Ross et al. 2009). Based upon these findings, the U.S. Food and Drug 
administration (FDA) changed the cisplatin label in 2011 to indicate the association with 
TPMT (U.S. Food and Drug Administration):  
“Certain genetic variants in the thiopurine S-Methyltransferase gene (e.g., TPMT*3B and 
TPMT*3C) are associated with an increased risk of ototoxicity in children administered 
conventional doses of cisplatin […] Twenty-six of the 162 patients had one or more TPMT 
gene variants. Of these 26 patients, 25 had severe ototoxicity (96%). For Caucasians and 
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African Americans, approximately 11% of the population inherit one or more of these 
variants.”   
A study investigating the economic impact of genetic testing for this, based on Ross et al.’s 
findings, estimated that by administering the test, potentially $ 19.6 million could be saved 
(Dionne et al. 2011). Furthermore, it was estimated, that of about one third of children 
expected to test positive, serious ototoxicity could be prevented depending on the 
availability of alternative treatment providing the same rate of cure. However, about 50% of 
those testing negative would still develop serious hearing impairment. 
4.2 Aim 
The aim of this study was to test for an association between the described variants in the 
TPMT and COMT genes and cisplatin-induced hearing loss, in a carefully phenotyped UK 
paediatric cohort.  
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4.3 Materials and Methods 
This study was a sub-study of the Molecular Genetics of Adverse Drug Reactions in Children 
(MAGIC) study, which is a retrospective, multicentre case-control study, focusing on the 
pharmacogenomic analysis of adverse drug reactions in children and has a generic study 
protocol and generic CRF. However, each MAGIC sub-study requires additional study specific 
information which must be recorded on additional pages added to the CRF and more 
importantly also requires specific instructions explaining the scientific background, how 
patients are identified, how the phenotype is defined etc. This information is similar to that 
generally described in a study protocol, however given that a generic study protocol exists 
and has ethical approval for the MAGIC study, the study specific details for this study were 
comprised in a cisplatin-ototoxicity study guide  
The author of this thesis planned this sub-study with regards to patient identification at Alder 
Hey, development of a study guide and additional pages for the CRF. She recruited patients, 
collected DNA samples, extracted data from clinical notes, helped to develop the database, 
entered data into the database, performed data control (CRF and database). She assessed 
and graded all audiograms (4.3.10). 
Details of the author’s contribution to the laboratory work and analysis of this study are 
outlined below. 
4.3.1 Study design 
Participants were recruited to the MAGIC study. For this sub-study, children with cancer 
were recruited from six UK paediatric oncology centres: Alder Hey Children’s NHS 
Foundation Trust, Liverpool; Royal Manchester Children’s Hospital, Manchester; Royal 
Victoria Infirmary, Newcastle; Leeds General Infirmary, Leeds; Great Ormond Street Hospital, 
London; Nottingham Children’s Hospital, Nottingham. 
The author of this thesis recruited patients at Alder Hey Children’s centre 
4.3.2 Inclusion criteria: 
For inclusion into the study patients needed to have  
1) started cisplatin on or after 1st January 2001, and,  
2) had at least one evaluable audiogram following the last dose of cisplatin (post treatment 
audiogram). To be considered evaluable, the audiogram had to fulfil the following criteria: 
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Either pure tone audiogram (PTA) or visual response audiogram (VRA) in decibel hearing 
level (db HL) and tested at 1, 2 and 4 kilo Hertz (kHz) and either 6 or 8 kHz.  
4.3.3 Exclusion criteria:  
The exclusion criteria were as follows: 
1) Parent/guardian unwilling to take part (if participant <16 years at time of recruitment).  
2) Participant unwilling to consent (if >16 years at time of recruitment). 
3) Competent participant unwilling to assent (competence assessed on a case by case basis).  
4) Hearing impairment prior to cisplatin treatment. 
5) No evaluable post treatment audiogram.  
6) Patient was, in the opinion of the investigator or the clinical team, not suitable to 
participate in the study for other reasons. 
4.3.4 Recruitment 
With permission of the patient’s named paediatric oncology consultant, patients and/or 
parents/guardians were approached. Patients or parents/guardians were provided with 
verbal information about the study by a study team member, usually a research nurse, and 
given information leaflets, including age appropriate leaflets for patients under 16 years. 
Informed written consent was then sought once the patient or parent/guardian had had time 
to read and understand the information leaflet (at least 24 hours after receiving the 
information). 
4.3.5 Consent 
All patients aged > 16 years at the time of recruitment, possessing the capacity to consent, 
were required to give written informed consent.  For patients < 16 years of age or patients 
aged > 16 years, who lacked capacity to consent, written informed consent from a parent or 
guardian was required. Assent was sought from those able to understand (assessed on a case 
by case basis). 
4.3.6 Ethical considerations 
This study was part of the MAGIC study and had ethical approval. Research Ethics No: 
10/H1002/57.  
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4.3.8 Patient enrolment, data collection and storage 
Patients were enrolled by the local study team member, usually a research nurse, at the 
participating centre. Data on date of birth (Dob), gender, ethnicity (White, black African, 
Indian, black Caribbean, black other, Bangladeshi, Pakistani, Chinese, other), diagnosis, 
treatment details (cisplatin doses, date of administration, concomitant vincristine use, 
cranial radiotherapy) and hearing tests, were collected retrospectively from medical case 
notes, prescription charts and audiology records, using a specifically designed case record 
form (CRF). Anonymised paper copies of audiograms and tympanograms were attached to 
the CRFs and both were forwarded to the lead study team in Liverpool where data were 
subsequently entered onto the study database. Patient age in this study was defined as age 
at start of cisplatin treatment, and was calculated using the following formula: 
Age = Dob – date of first dose of cisplatin. 
4.3.9 Genetic samples and genotyping 
Unless stated otherwise, all chemicals were obtained from Sigma-Aldrich, 
www.sigmaaldrich.com. 
4.3.9.1 DNA collection and extraction and purification 
Patient samples were collected as whole blood ethylenediaminetetraacetic acid (EDTA) 
samples or saliva.  The preferred sampling method was whole blood and a minimum of 2.6 
ml per sample was required. Whole blood samples were stored at -80°C. DNA from saliva 
was captured and stabilised using the OrageneTM DNA collection Kit (OG-575) for assisted 
collection (DNA Genotek Inc. Ontario, Canada; www.dnagenotek.com). Following collection 
of the sample, and mixing with the Oragene DNA preserving solution, samples were stored 
at -80°C. DNA extraction and archiving was performed at the Wolfson Centre for 
Personalised Medicine, Department of Pharmacology, University of Liverpool.  
The author of this thesis performed the extraction of DNA from saliva and whole blood.  
4.3.9.2 DNA extraction and purification from saliva  
For genomic DNA extraction and purification from saliva samples, the Oragene DNA kit (DNA 
Genotek Inc. Ontario, Canada; www.dnagenotek.com) was used. Samples were defrosted for 
1 hr in at room temperature (RT) and then incubated in a water incubator at 50°C for a 
minimum of 1 hour. After that, Oragene DNA Purifier was added 1:25 to each sample, e.g. 
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160 l purifier was added to 4ml saliva, and mixed by vortexing for a few seconds. Samples 
were then incubated on ice for 10 minutes and following this centrifuged at 4600 x g for 10 
minutes. An equal volume of 95% ethanol was added to each resulting supernatant and the 
pellet discarded. After that, samples were mixed 10 times by inversion and left to stand at 
RT for 10 minutes.  Then, samples were centrifuged at 4600 x g for 10 minutes. The resulting 
supernatant of each sample was discarded and the DNA pellet rinsed with 1ml 70% ethanol 
and then left to stand at RT for 1 min. Samples were rehydrated by addition of 500 l Tris-
EDTA (TE) buffer and mixed by vortexing for 30 seconds. Following this, samples were stored 
at -20°C and rehydration assessed after 7 days. If rehydration was incomplete, additional 
cold storage was undertaken for another 7 days.  
4.3.9.3 DNA extraction from whole blood  
EDTA blood samples were defrosted at RT for 30 min. Genomic DNA was extracted using the 
Chemagen whole-blood DNA extraction kit on the Chemagic Magnetic Separation Module I, 
according to the manufacturer's protocol (PerkinElmer Chemagen Technologie GmbH, 
Baesweiler, Germany; www.chemagen.com).  
4.3.9.4 Quantification and normalisation of DNA  
Quantification of DNA was carried out using a NanoDrop 8000 spectrophotometer (Thermo 
Fisher scientific, Waltham, USA; www.thermofisher.com). DNA was normalised to 20 ng/l 
on a liquid handler Biomek NXP, using Biomek software (Beckman Coulter (UK) Ltd; 
www.beckmancoulter.com). 
The author of this thesis carried out quantification using Nanodrop and prepared the 
samples for normalisation. The liquid handler was operated by Dr Eunice Zhang (EZ). 
4.3.9.5 Genotyping 
Genotyping was undertaken for three TPMT variants (rs12201199, rs1142345 and 
rs1800460) and two COMT variants (rs4646316 and rs9332377) as described by Ross et al. 
(Ross et al. 2009), using an ABI 7900HT Real time PCR System, Taqman chemistry and SDS 
plate utility software version 2.3 (all Thermo Fisher Scientific, Waltham, USA; 
www.thermofisher.com). PCR was carried out using Taqman Drug metabolism genotyping 
Assays C__19567_20, C__31923406_10, C__30634116_20, C__29193982_10, 
C__29614343_10 and C__11643398_10. A reaction volume of 6 µl contained 10 ng DNA, 1X 
Taqman master mix and 1X Taqman drug metabolising genotyping assay mix. To minimise 
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cross contamination of samples, a dry-down DNA method was performed according to the 
manufacturer’s protocol.  The PCR conditions were as follows: activation of AmpliTaq Gold 
DNA polymerase at 95°C for 10 min, followed by 40 cycles of (1) denaturing at 95°C for 15 
sec and (2) extension at 60°C for 90 sec.  Alleles were clustered using fluorescent signals (VIC 
and FAM). As part of quality control, 10% of samples were analysed as duplicates and one 
negative control was included per 96 samples. To avoid bias, the phenotypical classification 
was carried out without knowledge of genotype.  
The author of this thesis assisted in the preparation of the genotyping assay and mixed the 
reagents. The assay was carried out by EZ in the presence of the author of this thesis 
4.3.10 Phenotyping  
To replicate the originally described cohort as closely as possible, all audiograms were graded 
according to CTCAE (National Cancer 2010; Ross et al. 2009) (Table 4.3). 6 kHz test results 
were accepted when 8 kHz results were not available. If several post treatment audiograms 
were provided, the audiogram showing the worst sensorineural hearing loss was used for 
grading. For patients with asymmetric hearing loss, both ears were graded separately and 
the results of both grades analysed as outlined below. All audiograms were assessed and 
graded centrally by the author of this thesis. Ambiguous cases were discussed with a second 
reviewer, a Consultant Paediatric Oncologist (BP) with expertise in cancer treatment related 
ototoxicity. Patients with audiograms that did not meet the inclusion criteria (4.3.2.) were 
withdrawn from the study at this stage. 
Table 4.3 CTCAE ototoxicity grading criteria as used by Ross et al. (Ross et al. 2009) 
Grade CTCAE criteria  
0 < 20 db at all frequencies 
1 > 20 db at 8 kHz* 
2 > 25 db at 4 kHz and above 
3 > 25 dB at 2 kHz and above  
4 > 40  dB at 1 kHz and above 
*6 kHz test results were accepted for grading where 8 kHz results were not available. 
4.3.11 Statistical Analysis  
The analysis was planned and conducted by Dr Peng Yin and Dr Andrea Jorgensen. The author 
of this thesis worked with the team of statisticians to provide the clinical context. She also 
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summarised the data for patient demographics and compared allele frequencies with 
population data from the 1000 genomes project (Table 4.5) 
Quality control procedures were applied to the genotype data and individuals or SNPs 
included in the analysis, based on the following criteria: sample call rate (samples missing 2 
or more SNPs were excluded), SNP call rate (only SNPs with a call rate > 95% were included), 
minor allele frequency (MAF) (only SNPs with a MAF > 0.01 were included) and Hardy-
Weinberg (HW) test (only SNPs with a HW test p-value > 0.05 were included). An additive 
mode of inheritance was assumed with SNPs coded 0, 1 or 2 to represent wild-type 
homozygotes, heterozygotes and mutant-type homozygotes respectively.  
Univariate and multivariate analyses were undertaken using ‘R’ version 3.2.0. First, a 
univariate multinomial logistic regression model was fitted to each non-genetic factor in 
turn. Next, multivariable multinomial logistic regression models were fitted to each SNP in 
turn. For each SNP two models were fitted. The first model included covariates to represent 
all non-genetic factors with p<0.25 univariately. Backward stepwise variable selection was 
applied to this baseline model, to remove any covariates no longer significant in the 
multivariable model, with an inclusion p-value=0.25 and an exclusion p-value=0.10. The final 
model was called the ‘baseline model’. The second model was the same as the baseline 
model but also included a covariate to represent the SNP and was called the ‘genetic model’. 
The likelihood ratio test was applied to compare the two models and thus assess for 
statistical significance of the SNP. P-values were adjusted using Bonferroni correction for 
multiple testing, adjusting for 5 tests (5 SNPs). In cases of asymmetric hearing loss, the worse 
ear grade was used as final ototoxicity grade.  
To avoid bias arising from this approach, a sensitivity analysis was carried out, using the 
ototoxicity grade of the better ear as final grade. Further sensitivity analyses of ototoxicity 
grades were performed by dichotomising outcomes in three different ways: CTCAE grade 0 
vs. 1-4; CTCAE grade 0 vs. 2-4; CTCAE grade 0 vs. 3-4. The approach to the sensitivity analyses 
was the same as for the ordinal outcome but logistic regression models were used, instead 
of multinomial logistic regression models.    
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4.4 Results  
149 patients were enrolled in the study and included in the genotyping assay but data was 
not available for six. 23 patients did not have the required audiograms and were therefore 
also withdrawn. For the 10 of these, post treatment audiograms did not include frequencies 
> 4kHz and for 13, no post treatment audiology records were available: one child died, one 
moved out of the region, two children had their audiograms performed at other hospitals, 
one child relapsed and required further treatment, for one child all audiology records were 
lost and for 7 children the reason was unclear.  
Audiograms from the remaining 120 patients were evaluated according to CTCAE criteria. 
4.4.1 Genomic quality controls  
Four patients were removed from the analysis after quality control as two or more SNPs were 
missing. All variants had a MAF > 5% and all passed the HW test (p-values > 0.05).  
4.4.2 Patient demographics 
The distribution of tumour types was: medulloblastoma 30.2% (35/116), other CNS tumours 
14.7% (17/116), osteosarcoma 24.1% (28/116), hepatoblastoma 12.9% (15/116), 
neuroblastoma 12.9% (15/116) and other non-CNS tumours 5.2% (6/116). 12 patients only 
experienced hearing loss in one ear. Considering the CTCAE grade of the worse ear, 90/116 
patients (77.6%) experienced hearing loss vs 78/116 patients (67.2%) when considering the 
better ear (CTCAE grade 0).  
Patients were between 7 months and 18.6 years old. The median age was 7.1 years and 92% 
were younger than 16 years, when they started cisplatin treatment. For two children, the 
age at start of treatment could not be calculated (4.3.7) due to a CRF completion error: DoB 
given was chronologically later than date of first dose of cisplatin given. The self-reported 
ethnicity for 89.4% (101/113) patients was Caucasian, for 5% (6/116) Asian, for 2.5% African 
(3/116) and for three children unknown.  
18.1% (21/116) of patients received cisplatin and carboplatin as part of the same treatment 
protocol. Of the remaining patients 56.9% (66/116) were not exposed to carboplatin at all, 
one patient was exposed to carboplatin before cisplatin treatment was started, and 22.4% 
(26/116) where exposed to carboplatin after having completed cisplatin treatment. Patients 
in this last group may have been changed from cisplatin to carboplatin therapy due to 
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nephrotoxicity or ototoxicity. Further characteristics are shown in Table 4.4 Patient 
characteristics and results of the univariate analysis using the worse ear grade in cases of 
asymmetric hearing loss.  
4.4.3 Results of univariate analysis  
In the univariate analysis ototoxicity was shown to be significantly (p < 0.05) associated with 
age, gender, cumulative dose of cisplatin, cranial irradiation and concomitant exposure to 
vincristine (Table 4.4). Ethnicity and concomitant use of carboplatin was not associated with 
an increased risk of hearing loss.   
4.4.4 Analysis of COMT and TPMT risk genotype association  
Clinical factors included in the multivariable model (p<0.25) were patient age at diagnosis, 
gender, cranial irradiation, cumulative dose of cisplatin, exposure to vincristine and 
carboplatin (Table 4.4). On applying variable selection to the model including all these 
factors, vincristine was removed due to correlation with cranial irradiation (r = 0.52). The 
allele frequency in this population was compared to population data from the 1000 genomes 
project (Auton et al. 2015) and showed similar distribution (Table 4.5). None of the 5 SNPs 
was significantly associated with hearing loss, with none of the corrected p-values reaching 
the significance threshold of p < 0.05. In sensitivity analyses, using 1) better ear and ordinal 
outcomes (Table 4.6), 2) worse ear and binary outcomes (Table 4.7) and 3) better ear and 
binary outcomes (Table 4.8), there was still no significant association for any of the variants.
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Grade 1  
(n=8) 
Grade 2  
(n=41) 
Grade 3  
(n=35) 
















Ethnicity       
     White 23 (22.8%) 7 (6.9%) 33 (32.7%) 33 (32.7%) 5 (5.0%) 0.45 
     Non-white 3 (25.0%) 0 (0.0%) 6 (50.0%) 2 (16.7%) 1 (8.3%) 
Gender       
     Male 17 (23.0%) 6 (8.1%) 32 (43.2%) 15 (20.3%)  4 (5.4%)  0.030 
     Female 9 (21.4%) 2 (4.8%) 9 (21.4%)  20 (47.6%) 2 (4.8%) 
Cumulative cisplatin dose (mg/m2)   












Cranial irradiation       
     YES 3 (7.5%) 2 (5.0%) 16 (40.0%) 17 (42.5%) 2 (5.0%) 0.028 
     NO 23 (30.3%) 6 (7.9%) 25 (32.9%) 18 (23.7%) 4 (5.3%) 
Vincristine       
     YES 9 (14.3%) 2 (3.17%) 22 (34.9%) 25 (39.7%) 5 (7.94%) 0.0091 
     NO 17 (32.1%) 6 (11.3%) 19 (35.8%) 10 (18.9%) 1 (1.89%) 
Carboplatin + Cisplatin*       
     YES 2 (9.52%) 0 (0%) 8 (38.1%) 10 (47.6%) 1 (4.76%) 0.097 
      NO 24 (25.3%) 8 (8.42%) 33 (34.7%) 25 (26.3%) 5 (5.26%) 
Total number of patients = 116. Data are presented as number (%) of patients unless otherwise indicated. *YES refers to patients who received cisplatin and carboplatin as part of the same 
treatment protocol. NO refers to patients who were not exposed to carboplatin whilst they were also treated with cisplatin. Patients in the latter group may have been changed from cisplatin 
to carboplatin
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Table 4.5 Allele frequency for the five SNPs and comparison to population data from the 
1000 genomes project (Auton et al. 2015) 
SNP Allele Frequency in the study 
population; N (%) 
Frequency in 1000 genomes 
all European 
COMT_rs9332377 C 192 (82.7%) 82.8% 84.9% 
T 40   (17.3%) 17.2% 15.1% 
COMT_rs4646316 C 184 (79.3%) 78.2% 75.3% 
T 48   (20.7%) 21.8% 24.7% 
TPMT_rs12201199 A 209 (90.1%) 83.7% 95.1% 
T 23   (9.9%) 16.3% 4.9% 
TPMT_rs1142345 T 216  (93.1%) 96.1% 97.1% 
C 16    (6.9%) 3.9% 2.1% 
TPMT_rs1800460 C 221  (95.3%) 98.7% 97.2% 
T 11    (4.7%) 1.3% 2.8% 
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Table 4.6 COMT and TPMT genetic variants association using CTCAE grading and ordinal outcomes; results of multivariable ordinal  
logistic regression analysis 
  Worse ear  Better ear  




Grade 1 vs Grade 0: 
Grade 2 vs Grade 0: 
Grade 3 vs Grade 0: 























































































































































*Determined using Bonferroni-corrected p-values, comparing to a significance threshold of p < 0.05. SE=Standard error 
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Table 4.7 COMT and TPMT genetic variants association using worse ear grade and dichotomised outcomes; results of the multivariable  
logistic regression analysis  
  CTCAE grade 0 vs. 1-4 CTCAE grade 0 vs. 2-4 CTCAE grade 0 vs. 3+4 
Gene SNP (reference) Estimate(SE) P-valuea Adjusted 
p-value* 
Estimate (SE) P-value Adjusted 
p-value* 
Estimate (SE) P-value Adjusted 
p-value* 
COMT rs9332377 (CC) 0.061  (0.44) 0.89 1.00 -0.19 (0.47) 0.69 1.00 -0.21 (0.57) 0.71 1.00 
 rs4646316 (CC) 0.058  (0.48) 0.90 1.00 0.012 (0.49) 0.98 1.00 -0.35 (0.62) 0.58 1.00 
TPMT rs12201199 (AA) -1.41 (0.60) 0.020 0.10 -1.54 (0.66) 0.019 0.095 -1.85 (0.84) 0.028 0.14 
 rs1142345 (TT) -0.73 (0.63) 0.25 1.00 -0.85 (0.68) 0.21 1.00 -1.13 (0.90) 0.21 1.00 
 rs1800460 (CC) -0.28 (0.69) 0.68 1.00 -0.41  (0.73) 0.58 1.00 0.38 (1.01) 0.71 1.00 
*Determined using Bonferroni-corrected p-values, comparing to a significance threshold of p < 0.05. SE=Standard error. 
 
Table 4.8 COMT and TPMT genetic variants association using better ear grade and dichotomised outcomes; results of the multivariable  
logistic regression analysis  
  CTCAE grade 0 vs. 1-4 CTCAE grade 0 vs. 2-4 CTCAE grade 0 vs. 3+4 
Gene SNP (reference) Estimate(SE) P-valuea Adjusted 
p-value* 
Estimate (SE) P-value Adjusted 
p-value* 
Estimate (SE) P-value Adjusted 
p-value* 
COMT rs9332377 (CC) -0.55 (0.40) 0.17 0.85 -0.58 (0.41) 0.16 0.80 -1.20 (0.70) 0.088 0.44 
 rs4646316 (CC) 0.27 (0.44) 0.54 1.00 0.31 (0.44) 0.49 1.00 0.16  (0.62) 0.80 1.00 
TPMT rs12201199 (AA) -0.94 (0.56) 0.097 0.49 -0.88 (0.57) 0.12 0.60 -1.91 (1.04) 0.067 0.34 
 rs1142345 (TT) -0.49  (0.61) 0.42 1.00 -0.43 (0.61) 0.48 1.00 -1.61 (1.31) 0.22 1.00 
 rs1800460 (CC) -0.21 (0.67) 0.75 1.00 -0.16  (0.67) 0.82 1.00 -15.1 (1.68) 0.99 1.00 
*Determined using Bonferroni-corrected p-values, comparing to a significance threshold of p < 0.05. SE=Standard error 
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4.5 Discussion  
This study was planned in 2010. Whilst most patients from Alder Hey were recruited by 2012, 
there was considerable delay in recruitment of patients and extraction of clinical data from 
other centres. Once genotyping and phenotyping data were available for patients included 
in this study, there was further delay with regards to the generic database, which in turn 
delayed the analysis. By the time this study was concluded, several other studies had been 
published which had also attempted replication of Ross et el.’s findings. In addition, further 
genes for cisplatin induced ototoxicity have been proposed since, namely ABCC3 and ACYP2 
which are discussed below. 
This study did not replicate TPMT and COMT as risk factors for cisplatin related hearing loss 
in paediatric cancer patients. Comparing our study population to that of Ross et al., gender 
distribution and age range were similar (Ross et al. 2009)(Table 4.4). The median cumulative 
dose of cisplatin in our study was lower (350 mg/m2 vs 400 mg/m2) and more children 
experienced hearing loss (77.6% vs 65.4%). The distribution of tumour types differed, in that 
twice as many children in this study had brain tumours (44.8% vs 20%), with nearly twice as 
many being exposed to cranial radiotherapy (34.5 % vs 18.5%) and ten times as many 
patients receiving vincristine (54.3% vs 5.5%). Ross et al. did not include carboplatin in the 
list of concomitant medications.  
4.5.1 Non-genetic influencing factors  
This study confirms known risk factors for cisplatin therapy induced ototoxicity in children 
such as increasing cumulative dose of cisplatin (Brock et al. 1991; Coradini et al. 2007; Li, 
Womer & Silber 2004; McHaney et al. 1983; Yancey et al. 2012), younger age (Coradini et al. 
2007; Li, Womer & Silber 2004; Yang et al. 2013), cranial radiotherapy (Hua et al. 2008; 
Paulino et al. 2010; Schell et al. 1989), male gender (Yancey et al. 2012; Yang et al. 2013) and 
concomitant exposure to vincristine (Pussegoda et al. 2013). Ethnic origin as a risk factor for 
hearing loss in patients receiving cisplatin therapy, was not detected. However, with nearly 
90% of the study population being Caucasian, the study did not have enough power to detect 
an effect of ethnicity.  
Patients in this study who received carboplatin and cisplatin combined were not at a higher 
risk of experiencing hearing loss. This is not unexpected. Most children who experience 
hearing loss after carboplatin therapy, have also received cisplatin and/or have received 
high-dose carboplatin regimens prior to stem cell transplant (Landier et al. 2014; Parsons et 
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al. 1998; Punnett et al. 2004). Children who receive standard dose carboplatin alone 
experience no or only mild hearing loss (Bertolini et al. 2004), indeed carboplatin is often 
used as an alternative to cisplatin, once significant ototoxicity has been confirmed. One of 
the limitations of this study is that the retrospective study design did not make it feasible to 
collect detailed dosage data of concomitant medications. Of the 95 children in this study who 
did not receive combined cisplatin and carboplatin therapy, 26 received carboplatin after 
cisplatin therapy, likely as alternative therapy due to cisplatin-induced nephro- or 
ototoxicity. 24/26 children in this group also had grade 2-4 hearing loss. Of the remaining 
two children, one had grade 2 hearing loss in the worse ear and the other grade 1 hearing 
loss. It is therefore possible that any effect from the combined exposure to cisplatin and 
carboplatin could have been underestimated. In addition, the median cumulative dose in 
patients who received carboplatin and cisplatin was lower (320 mg/m2) compared to those 
who didn’t (360 mg/m2).  
For pragmatic reasons, exposure to aminoglycosides or furosemide was not investigated in 
this study: gentamicin is commonly used in the treatment of febrile neutropenia in the UK. 
Due to the setup of paediatric cancer treatment in the UK, many children in our cohort will 
have received any treatment for febrile neutropenia in shared care units and it would 
therefore not have been feasible to the relevant collect treatment data. The same applies to 
the use of furosemide, e.g. in conjunction with transfusion of blood products which is also 
frequently done in shared care units. Furthermore, although ototoxicity is listed in the 
adverse drug reaction profile in the SmPC for furosemide as well as aminoglycosides 
(DataPharm Communications Ltd. 2010), several studies that did include these medicines, 
did not find an association in patients with cisplatin-induced hearing loss (Punnett et al. 
2004; Pussegoda et al. 2013; Ross et al. 2009; Yancey et al. 2012). In contrast, an increased 
risk of hearing loss was observed in high-risk neuroblastoma patients admitted to hospital 
for infection during the induction phase of their treatment (Landier et al. 2014) and the 
authors of the study suggested this was a surrogate for additional ototoxic exposure, such 
as aminoglycoside use. Finally, aminoglycoside induced ototoxicity has been linked to 
mutations of the mitochondrial MT-RNR1 Gene (Usami et al. 1998). Given a population 
prevalence in Caucasian children of approx. 1:500 (Bitner-Glindzicz et al. 2009), it is unlikely 
that more than one child in our cohort was a mutation carrier and this would therefore not 
have biased the results. 
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Association of TMPT and COMT variants in other studies 
To date, the evidence for the association of variants in the TPMT and COMT genes with 
cisplatin-induced hearing loss remains controversial. Pussegoda et al. confirmed the 
association with TPMT but not COMT in a cohort of 155 patients (Pussegoda et al. 2013) , 
but Yang et al. did not find an association with any of the variants in either gene in a study 
of 213 paediatric medulloblastoma patients (Yang et al. 2013). Hagleitner et al. investigated 
the proposed variants in a Dutch cohort of 110, and a Spanish cohort of 38 patients and again 
demonstrated a lack of association (Hagleitner et al. 2014). However, Hagleitner et al. also 
performed a meta-analysis including all the above studies and found that the rs4646316 
variant in the COMT gene was significantly associated with ototoxicity. Since then, Lanvers-
Kaminsky et al. did not find an association any of the described variants in their cohort of 63 
children (Lanvers-Kaminsky et al. 2014). Moreover, the FDA approved drug label for cisplatin 
was amended in 2015 to reflect this uncertainty (U.S. Food and Drug Administration):  
“Genetic factors (e.g. variants in the thiopurine S-Methyltransferase [TPMT] gene) may 
contribute to cisplatin-induced ototoxicity; although this association has not been consistent 
across populations and study designs.” 
4.5.2 Implications of results 
It is interesting that the only two studies demonstrating an association with any of the 
described TPMT and COMT variants were much larger, i.e. the meta-analysis by Hagleitner 
et al. (Hagleitner et al. 2014) and/or very closely resembled the study population and 
methods of the original study, i.e Pussegoda et al. (Pussegoda et al. 2013).  The most likely 
reasons for the lack of association in this study as well as in other studies is probably due to 
the heterogeneity between study populations as outlined above (4.1.2). This has already 
been discussed by Hagleitner, Yang and Carleton, all highlighting critical differences between 
their respective studies that might mask genetic susceptibility findings (Carleton et al. 2014; 
Hagleitner et al. 2014; Yang et al. 2013). Association studies of SNPs with adverse drug effects 
are known to be at risk of producing false positive or false negative results, especially if the 
study population is small and the association is examined in stratified groups of the 
population (Royal Society Working Group 2005). The aim of additional sensitivity analysis in 
this study was to address these issues, but the results remained the same.   
A factor that has not been regularly discussed, but may have a significant impact on any study 
investigating cisplatin-induced ototoxicity, is the grading of asymmetric hearing loss, i.e. 
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worse ear vs. better ear. Whilst it is clinical practice in the UK to use Brock ototoxicity grading 
and to use the better ear to assign the overall grade, other classifications, such as Chang, 
CTCAE and the new SIOP Boston scale (Brock et al. 2012) do not stipulate how to proceed in 
such cases (Gurney & Bass 2012). Yang et al. used the worse ear to grade ototoxicity but few 
other authors have described how they proceeded in their study population. In this study, 
the number of patients with different grades of hearing loss in both ears was 10.3% (12/116). 
Assuming a similar percentage of patients with asymmetric hearing loss in other study 
populations, this could have led to a significant number of misclassifications and may have 
added to the difficulties in trying to replicate the association.  
As already discussed by Yang et al. the association between COMT, TPMT and cisplatin 
induced hearing loss was not expected (Yang et al. 2013). TPMT metabolises thiopurines, 
such as the immunosuppressant and antineoplastic 6-MP. TPMT deficiency has significant 
implications for treatment with thiopurines, which has already been highlighted at the 
beginning of this thesis (1.6.5). COMT interacts with S-adenosylmethionine (SAM) and 
although COMT has been has been linked to sensorineural hearing loss in mice and humans 
(Du et al. 2008), it is predominantly linked with psychiatric disorders such as schizophrenia 
(McKusick 2007) and the biological mechanism for cisplatin induced hearing loss remains 
unclear. 
Since Ross et al. first published their findings, 2 other genetic variants have been proposed. 
ABCC3  SNP rs1051640 (Pussegoda et al. 2013) and ACYP2 SNP rs1872328 (Xu et al. 2015). 
The same SNP for ABCC3 had already been investigated by Ross et al. in 2009, but no 
significant association had been found in the original cohort (Ross et al. 2009). The ACYP2 
variant was first was identified using a genome-wide association study in 238 children with 
brain tumours (Xu et al. 2015), which was replicated within the original study. An additional 
study has also recently replicated the association with ACYP2 in patients (n=156) with 
osteosarcoma (Vos et al. 2016). Furthermore, association between the  ACYP2 polymorphism 
and cisplatin induced hearing loss has also been replicated in the cohort that was used for 
this study and was confirmed in a meta-analysis(Thiesen et al. 2017)  
4.6 Conclusion  
This study did not confirm an association with TPMT and COMT and cisplatin-induced hearing 
loss. Cisplatin is used in a wide variety of tumours, and patient heterogeneity is thus likely to 
be a confounding factor. Meta-analyses have since shown an association with COMT 
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rs464316 SNP. Further studies in larger populations and including the more recently 
described association with ACYP2 SNP rs1872328, would still be beneficial in order to define 
factors that modulate this association. We also need to understand the biological basis of 
the genetic associations 
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5 Final Discussion  
5.1 ADRs in hospitalised children - summary of findings, interpretation and 
implications for research  
In this thesis, adverse drug reactions occurring in children after admission to hospital were 
investigated. It is the largest prospective inpatient study so far.  The study included general 
paediatric patients, as well as a large variety of patients from different paediatric surgical 
and medical specialities. ADRs were characterised in terms of type of reaction, causality and 
medications suspected to have caused the reaction. Incidence rates were calculated and 
factors associated with an increased risk of experiencing an ADR were identified. Considering 
the first admission only, incidence of ADRs was 43.7% in the Oncology population and 14.0% 
in the non-Oncology population. Opiate analgesics and drugs used during GA were the most 
commonly implicated medications. Less than 1% of ADRs lead to permanent harm or resulted 
in patient transfer to higher level of care and no ADR was associated with death.  
Comparison of ADR incidence rates between this study and other recent adult and paediatric 
studies is problematic due to differences in methodology, specifically the use of other 
causality assessment tools and inclusion or exclusion of ‘possible’ ADRs. Risk factors 
identified in this study confirmed established risk factors such as the use of more than one 
medication and oncology treatment. ‘Undergoing a procedure under GA’, was a new and 
significant risk factor identified in this study and more than a third of patients who had 
undergone a GA and developed at least one ADR had experienced PONV. New consensus 
guidelines regarding the management and prevention of PONV have been published after 
this study was conducted (Gan et al. 2014; Martin et al. 2016). It will be important to 
investigate whether the overall risk of ADRs in children undergoing a GA has decreased since 
the implementation of these guidelines.  
There is good evidence from other areas of paediatric medicine that even common, benign 
and short lasting events such as febrile seizures, may be perceived as extremely frightening 
by parents (Baumer et al. 1981), and give rise to anxiety and disruption of family life well 
beyond the actual event (Wirrell & Turner 2001). Wirrel and Turner concluded that “the 
extreme fear felt by most parents is in sharp contrast to the physician’s perception that most 
febrile seizures are benign and are associated with a minimal risk of brain injury, death or 
subsequent epilepsy (Wirrell & Turner 2001)”. 
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Parents’ experience of ADRs was investigated as part of the ADRIC programme (Arnott et al. 
2012; Smyth et al. 2014) and the outcome suggests a similar discordance between clinicians’ 
and parents’ views: “Parents of children included in this study reported that suspected ADRs 
cause them concern irrespective of the ‘medical’ severity of the suspected reaction”. 
Importantly, Arnott et al. observed that parents of children receiving cancer treatment 
viewed the communication they received about ADRs as positive, whereas most other 
parents were dissatisfied with the communication about ADRs (Arnott et al. 2012; Smyth et 
al. 2014). They highlighted a case of a child with pruritus due to morphine, which clinically 
presented as agitation. This is a common dilemma in children who are unable to verbalise 
their itchiness or indicate it non-verbally e.g. by scratching. The parent, who was unaware 
that agitation could be a result of pruritus, interpreted the agitation as uncontrolled pain and 
continued to give booster doses of morphine which worsened the agitation. Scenarios like 
this are preventable by better communication about possible side effects of medication 
before they are given and perhaps this should form part of the routine pre-operative 
assessment.  
However, there is a paucity of studies investigating patients’, especially children’s, 
experience of ADRs. One adult study found that patients who reported possible ADRs 
experienced a reduction in health related quality of life. (Rolfes et al. 2016). Guo et al. 
reported that ADRs that required discontinuation of treatment or additional treatment led 
to reduction in health-related quality of life with particular negative impact on mental health 
(Guo et al. 2010). These aspects need to be investigated in the paediatric population  
The study did not assess avoidability of each ADR, due to the lack of a suitable assessment 
tool. A novel ADR assessment tool (AAT) developed specifically with the paediatric setting in 
mind, has been proposed since the study was conducted, but has so far  shown mixed inter-
rater reliability (Bracken et al. 2013). This is most likely a reflection of the complexity of the 
influencing factors. Determining the avoidability of ADRs would be a vital step towards the 
translation of research findings, such as those described in this thesis, into improved 
medicines safety for children. It would allow intervention efforts to be concentrated on those 
ADRs that are likely to be avoidable and help health care professionals when communicating 
about ADRs.  
Spontaneous reporting systems such as the UK yellow card scheme remain an important 
source of ADR signal detection. However, studies such as the retrospective study by Maitre 
et al. investigating adverse neurodevelopmental outcomes after exposure to antiepileptic 
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drugs (Maitre et al. 2013) highlight the ongoing importance of formal 
pharmacoepidemiological studies. This is not only because underreporting is a common 
problem of spontaneous reporting systems (Hawcutt et al. 2011), but also because late 
effects may be difficult to capture with this approach. More long term follow-up studies 
designed to monitor the effect of medicines on growth and (neuro-) development are 
required and projects like the Attention Deficit Hyperactivity Drug Use Chronic Effect 
(ADDUCE) project, investigating the long-term adverse effects of methylphenidate (The 
ADDUCE Consortium 2012), are aiming to address this.  
A recent systematic review of pharmacoepidemiology safety studies in children since 1979 
reported a significant imbalance with regards to the variety of drug classes investigated and 
safety outcomes considered (Osokogu et al. 2016). Furthermore, although the overall 
number of studies are increasing, the authors found a distinct lack of studies including 
neonates and suggested that some of the specific challenges such as small sample size and 
bias towards developed countries, may be overcome by international collaborations such as 
the Global Research in Paediatrics (GRiP) project (The GRiP consortium). In addition, a large 
amount of data is now being collected on electronic health records and data from electronic 
prescribing systems, thereby carrying an enormous potential for future pharmacovigilance 
and pharmacoepidemiological studies.  
Prospective review of potential ADRs, as conducted in this study, is a powerful tool but is 
resource-intensive. This approach is probably best used in clinical trials or targeted disease 
settings with a high burden of potentially preventable ADRs.  
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5.2 Financial burden of ADRs in children - summary of findings 
interpretation and implications for research 
This thesis also investigated the economic impact of ADRs in hospitalised children by 
assessing excess bed days caused by ADRs. Compared to adult studies, the financial impact 
in terms of hospital bed days was small. This might reflect the different spectrum of ADR 
types in children, the reduced number of comorbidities in children (and hence reduced 
number of drugs), their generally better health and shorter recovery times. Aside from 
limitations of the methodology which were discussed in chapter 3, determining excess LOS 
might not be the best proxy parameter to assess the financial impact of ADRs in children. 
ADRs with major clinical and personal impact, such as hearing loss, severe cardiomyopathy 
or neurodevelopmental deficits, can also be expected to have a significant financial impact. 
The cost of severe hearing loss has been highlighted in chapter 4, the cost of a heart 
transplant has been estimated to be $1 million (United Network for Organ Sharing (UNOS) 
2016), lifetime cost for an individual with an autistic spectrum disorder and a learning 
disability is estimated to be £ 4.7 million (Foundation for People with Learning Disabilities 
2007). To assess the financial impact of ADRs children it might therefore be conducive to 
focus on reaction types with an expected financial impact and to conduct detailed case based 
cost analyses.   
In adult populations ADRs have been shown to be one of the most important contributors to 
non-compliance with medication (Leporini, De Sarro & Russo 2014). This in turn frequently 
leads to preventable hospital admissions and preventable progression of chronic disease 
with significant health care cost implications (Iuga & McGuire 2014). It would be interesting 
to investigate the burden of this in the paediatric population.  
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5.3 Cisplatin-induced ototoxicity in paediatric cancer patients - summary 
of findings, interpretation and implications for research 
The association between variants in the TMPT and COMT genes and cisplatin-induced 
ototoxicity in form of hearing loss, was tested in a UK cohort of children. In this cohort, none 
of the TPMT and COMT polymorphisms was associated with hearing loss. However, 
combining data of this study with those of previous study the pooled odds ratio was 
statistically significant for the associations with the COMT SNP rs464316 (odds ration 1.53, 
95% CI:1.7-2.00, I2:5%)(Thiesen et al. 2017). This supports the findings from a previous meta-
analysis (Hagleitner et al. 2014), discussed in chapter 4. There remains considerable 
uncertainty about whether TMPT, COMT and other previously described genetic 
polymorphisms represent genuine risk factors for cisplatin-induced hearing loss.  
Heterogeneity between study populations remains a challenge for pharmacogenomic 
replication studies, notably in the paediatric population. Adequately powered paediatric 
studies can be achieved through collaboration projects and could reduce the potential for 
bias in this aspect (Maagdenberg et al. 2016). Whilst good quality evidence is of course the 
prerequisite for any advancement towards personalised medicine, translating this genetic 
evidence into clinical practice remains the foremost challenge (Maroñas et al. 2016). For 
example, aminoglycoside-induced hearing loss has been associated with several 
mitochondrial mutations. Mitochondrial inheritance had first suspected in 1991 (Hu et al. 
1991) clinical testing is now widely available for the most common mutation, A1555G. 
However routine pre-treatment screening has frequently been evaluated over recent years. 
In a detailed analysis by Veestra et al. ‘the potential clinical, patient and economic outcomes 
associated with the use of A1555G testing in a cystic fibrosis population’, i.e. a high risk 
population, were evaluated and the authors concluded that testing could not be 
recommended, potentially lead to worse patient outcomes by increasing the mortality risk 
from pseudomomas infections and might not even be cost-effective (Veenstra et al. 2007).  
For cisplatin induced ototoxicity, an additional genetic variant ACYP2 (rs1872328) has 
recently been identified by GWAS in a cohort of 238 children with brain tumours (Xu et al. 
2015). All patients who carried the variant in one or both alleles developed hearing loss, and 
none of the patients without hearing loss carried the variant. However, only 12.4 % of 
children with hearing loss also carried the risk allele (Xu et al. 2015). The findings have been 
replicated in two subsequent studies (Thiesen et al. 2017; Vos et al. 2016). Combining the 
data of all three studies in a meta-analysis the pooled odds ration remained significant (odds 
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ratio 5.91, 95% CI: 1.51-23.16). These results are promising. Indirectly, they also highlight the 
importance of accurate phenotyping. All three studies classified the ear with the worst 
hearing loss according to Chang criteria, which Chang developed specifically for the 
evaluation of cisplatin induced hearing loss in children (Chang & Chinosornvatana 2010). As 
discussed in chapter 4, most studies investigating cisplatin-induced ototoxicity in children did 
not report on asymmetric hearing loss which may have led to a significant degree of 
misclassification.  However, further studies need to confirm the association between ACYP2 
and cisplatin induce hearing-loss and further work is required to understand the association 
between risk genotypes and cisplatin-induced ototoxicity.  
Currently, the only way of preventing cisplatin-induced ototoxicity is by avoiding cisplatin 
treatment. The clinical utility of identifying genetic risk genotypes proactively is thus 
dependant on the availability of alternative treatment options. Currently, the alternative 
treatment offered to patients with established hearing loss is carboplatin. However, the 
effectiveness of carboplatin treatment is not as well established as for cisplatin and there is 
still a risk of severe hearing loss (Boddy 2013). It is therefore unlikely that parents of a child 
with cancer would choose anything but the treatment proven to most likely to safe their 
child’s life.  
Although progress has been made in uncovering the underlying biological mechanisms 
leading to cisplatin induced ototoxicity, crucial steps, such as how cisplatin/cisplatin 
metabolites enter the sensory hair cells, are still unclear (Callejo et al. 2015). Without this 
knowledge, successful translation into oto-protective treatment will remain a challenge. 
Whilst a number of oto-protective agents have been shown to be effective in pre-clinical 
experiments, many of them also reduce the therapeutic efficacy of cisplatin, which renders 
them unprofitable in clinical practice (Callejo et al. 2015). A recent Cochrane review update 
of ‘medical interventions for the prevention of platinum-induced hearing loss in children 
with cancer’ concluded that there is not enough evidence to give recommendations for 
clinical practice and that ‘more high quality research is needed’ (van As, van den Berg & van 
Dalen 2016). 
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5.4 Conclusion  
ADRs remain a significant cause of morbidity and mortality worldwide. ADRs occurring in 
children admitted to hospital are frequent, but rarely associated with permanent harm or 
death. Few studies to date have investigated the financial burden of ADRs in paediatric 
populations. The significant inter-individual differences in cisplatin-induced ototoxicity are 
far from being fully understood and evidence for genetic variants has been mostly 
controversial.  
Overall, increasing use of electronic clinical databases, electronic prescribing technology, 
national and international collaborations and advances in genomic technology, are providing 
vast opportunities for future research projects aiming to optimise treatment and improve 
medication safety for children. 
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